{
    "abstract": "Malaria continues to be one of the world's most devastating infectious tropical diseases, and alternative strategies to prevent infection and disease spread are urgently needed. These strategies include the development of effective vaccines, such as malaria transmission blocking vaccines (TBV) directed against proteins found on the sexual stages of Plasmodium falciparum parasites present in the mosquito midgut. The Pfs25 protein, which is expressed on the surface of gametes, zygotes and ookinetes, has been a primary target for TBV development. One such vaccine strategy based on Pfs25 is a plant-produced malaria vaccine candidate engineered as a chimeric non-enveloped virus-like particle (VLP) comprising Pfs25 fused to the Alfalfa mosaic virus coat protein. This Pfs25 VLP-FhCMB vaccine candidate has been engineered and manufactured in Nicotiana benthamiana plants at pilot plant scale under current Good Manufacturing Practice guidelines. The safety, reactogenicity and immunogenicity of Pfs25 VLP-FhCMB was assessed in healthy adult volunteers. This Phase 1, dose escalation, first-in-human study was designed primarily to evaluate the safety of the purified plant-derived Pfs25 VLP combined with Alhydrogel\u00ae adjuvant. At the doses tested in this Phase 1 study, the vaccine was generally shown to be safe in healthy volunteers, with no incidence of vaccine-related serious adverse events and no evidence of any dose-limiting or dose-related toxicity, demonstrating that the plant-derived Pfs25 VLP-FhCMB vaccine had an acceptable safety and tolerability profile. In addition, although the vaccine did induce Pfs25-specific IgG in vaccinated patients in a dose dependent manner, the transmission reducing activity of the antibodies generated were weak, suggesting the need for an alternative vaccine adjuvant formulation. This study was registered at www.ClinicalTrials.gov under reference identifier NCT02013687.",
    "author_highlights": [
        {
            "endOffset": 12128,
            "sentence": "Report of a Phase I clinical trial to assess a malaria transmission blocking vaccine.",
            "startOffset": 12043
        },
        {
            "endOffset": 12213,
            "sentence": "P. falciparum Pfs25 virus-like particle produced under cGMP in a plant-based system.",
            "startOffset": 12129
        },
        {
            "endOffset": 12291,
            "sentence": "The vaccine candidate displays an acceptable safety and tolerability profile.",
            "startOffset": 12214
        },
        {
            "endOffset": 12368,
            "sentence": "The vaccine candidate induced Pfs25-specific IgG in a dose dependent manner.",
            "startOffset": 12292
        },
        {
            "endOffset": 12454,
            "sentence": "However, low transmission reducing activity implies need for an improved formulation.",
            "startOffset": 12369
        }
    ],
    "bib_entries": {
        "b0005": null,
        "b0010": null,
        "b0015": {
            "authors": [
                {
                    "first": "Selidji Todagbe",
                    "initial": "S.T.",
                    "last": "Agnandji"
                },
                {
                    "first": "Bertrand",
                    "initial": "B.",
                    "last": "Lell"
                },
                {
                    "first": "Jos\u00e9 Francisco",
                    "initial": "J.F.",
                    "last": "Fernandes"
                },
                {
                    "first": "B\u00e9atrice Peggy",
                    "initial": "B.P.",
                    "last": "Abossolo"
                },
                {
                    "first": "Barbara Gaelle Nfono Ondo",
                    "initial": "B.G.N.O.",
                    "last": "Methogo"
                },
                {
                    "first": "Anita Lumeka",
                    "initial": "A.L.",
                    "last": "Kabwende"
                },
                {
                    "first": "Ayola Akim",
                    "initial": "A.A.",
                    "last": "Adegnika"
                },
                {
                    "first": "Benjamin",
                    "initial": "B.",
                    "last": "Mordm\u00fcller"
                },
                {
                    "first": "Saadou",
                    "initial": "S.",
                    "last": "Issifou"
                },
                {
                    "first": "Peter Gottfried",
                    "initial": "P.G.",
                    "last": "Kremsner"
                },
                {
                    "first": "Jahit",
                    "initial": "J.",
                    "last": "Sacarlal"
                },
                {
                    "first": "Pedro",
                    "initial": "P.",
                    "last": "Aide"
                },
                {
                    "first": "Miguel",
                    "initial": "M.",
                    "last": "Lanaspa"
                },
                {
                    "first": "John J.",
                    "initial": "J.J.",
                    "last": "Aponte"
                },
                {
                    "first": "Sonia",
                    "initial": "S.",
                    "last": "Machevo"
                },
                {
                    "first": "Sozinho",
                    "initial": "S.",
                    "last": "Acacio"
                },
                {
                    "first": "Helder",
                    "initial": "H.",
                    "last": "Bulo"
                },
                {
                    "first": "Betuel",
                    "initial": "B.",
                    "last": "Sigauque"
                },
                {
                    "first": "Eus\u00e9bio",
                    "initial": "E.",
                    "last": "Macete"
                },
                {
                    "first": "Pedro",
                    "initial": "P.",
                    "last": "Alonso"
                },
                {
                    "first": "Salim",
                    "initial": "S.",
                    "last": "Abdulla"
                },
                {
                    "first": "Nahya",
                    "initial": "N.",
                    "last": "Salim"
                },
                {
                    "first": "Rose",
                    "initial": "R.",
                    "last": "Minja"
                },
                {
                    "first": "Maxmillian",
                    "initial": "M.",
                    "last": "Mpina"
                },
                {
                    "first": "Saumu",
                    "initial": "S.",
                    "last": "Ahmed"
                },
                {
                    "first": "Ali Mohammed",
                    "initial": "A.M.",
                    "last": "Ali"
                },
                {
                    "first": "Ali Takadir",
                    "initial": "A.T.",
                    "last": "Mtoro"
                },
                {
                    "first": "Ali Said",
                    "initial": "A.S.",
                    "last": "Hamad"
                },
                {
                    "first": "Paul",
                    "initial": "P.",
                    "last": "Mutani"
                },
                {
                    "first": "Marcel",
                    "initial": "M.",
                    "last": "Tanner"
                },
                {
                    "first": "Halidou",
                    "initial": "H.",
                    "last": "Tinto"
                },
                {
                    "first": "Umberto",
                    "initial": "U.",
                    "last": "D'Alessandro"
                },
                {
                    "first": "Hermann",
                    "initial": "H.",
                    "last": "Sorgho"
                },
                {
                    "first": "Innocent",
                    "initial": "I.",
                    "last": "Valea"
                },
                {
                    "first": "Bi\u00e9bo",
                    "initial": "B.",
                    "last": "Bihoun"
                },
                {
                    "first": "Issa",
                    "initial": "I.",
                    "last": "Guiraud"
                },
                {
                    "first": "Berenger",
                    "initial": "B.",
                    "last": "Kabor\u00e9"
                },
                {
                    "first": "Olivier",
                    "initial": "O.",
                    "last": "Sombi\u00e9"
                },
                {
                    "first": "Robert Tinga",
                    "initial": "R.T.",
                    "last": "Guiguemd\u00e9"
                },
                {
                    "first": "Jean Bosco",
                    "initial": "J.B.",
                    "last": "Ou\u00e9draogo"
                },
                {
                    "first": "Mary J.",
                    "initial": "M.J.",
                    "last": "Hamel"
                },
                {
                    "first": "Simon",
                    "initial": "S.",
                    "last": "Kariuki"
                },
                {
                    "first": "Martina",
                    "initial": "M.",
                    "last": "Oneko"
                },
                {
                    "first": "Chris",
                    "initial": "C.",
                    "last": "Odero"
                },
                {
                    "first": "Kephas",
                    "initial": "K.",
                    "last": "Otieno"
                },
                {
                    "first": "Norbert",
                    "initial": "N.",
                    "last": "Awino"
                },
                {
                    "first": "Meredith",
                    "initial": "M.",
                    "last": "McMorrow"
                },
                {
                    "first": "Vincent",
                    "initial": "V.",
                    "last": "Muturi-Kioi"
                },
                {
                    "first": "Kayla F.",
                    "initial": "K.F.",
                    "last": "Laserson"
                },
                {
                    "first": "Laurence",
                    "initial": "L.",
                    "last": "Slutsker"
                },
                {
                    "first": "Walter",
                    "initial": "W.",
                    "last": "Otieno"
                },
                {
                    "first": "Lucas",
                    "initial": "L.",
                    "last": "Otieno"
                },
                {
                    "first": "Nekoye",
                    "initial": "N.",
                    "last": "Otsyula"
                },
                {
                    "first": "Stacey",
                    "initial": "S.",
                    "last": "Gondi"
                },
                {
                    "first": "Allan",
                    "initial": "A.",
                    "last": "Otieno"
                },
                {
                    "first": "Victorine",
                    "initial": "V.",
                    "last": "Owira"
                },
                {
                    "first": "Esther",
                    "initial": "E.",
                    "last": "Oguk"
                },
                {
                    "first": "George",
                    "initial": "G.",
                    "last": "Odongo"
                },
                {
                    "first": "Jon",
                    "initial": "J.",
                    "last": "Ben Woods"
                },
                {
                    "first": "Bernhards",
                    "initial": "B.",
                    "last": "Ogutu"
                },
                {
                    "first": "Patricia",
                    "initial": "P.",
                    "last": "Njuguna"
                },
                {
                    "first": "Roma",
                    "initial": "R.",
                    "last": "Chilengi"
                },
                {
                    "first": "Pauline",
                    "initial": "P.",
                    "last": "Akoo"
                },
                {
                    "first": "Christine",
                    "initial": "C.",
                    "last": "Kerubo"
                },
                {
                    "first": "Charity",
                    "initial": "C.",
                    "last": "Maingi"
                },
                {
                    "first": "Trudie",
                    "initial": "T.",
                    "last": "Lang"
                },
                {
                    "first": "Ally",
                    "initial": "A.",
                    "last": "Olotu"
                },
                {
                    "first": "Philip",
                    "initial": "P.",
                    "last": "Bejon"
                },
                {
                    "first": "Kevin",
                    "initial": "K.",
                    "last": "Marsh"
                },
                {
                    "first": "Gabriel",
                    "initial": "G.",
                    "last": "Mwambingu"
                },
                {
                    "first": "Seth",
                    "initial": "S.",
                    "last": "Owusu-Agyei"
                },
                {
                    "first": "Kwaku Poku",
                    "initial": "K.P.",
                    "last": "Asante"
                },
                {
                    "first": "Kingsley",
                    "initial": "K.",
                    "last": "Osei-Kwakye"
                },
                {
                    "first": "Owusu",
                    "initial": "O.",
                    "last": "Boahen"
                },
                {
                    "first": "David",
                    "initial": "D.",
                    "last": "Dosoo"
                },
                {
                    "first": "Isaac",
                    "initial": "I.",
                    "last": "Asante"
                },
                {
                    "first": "George",
                    "initial": "G.",
                    "last": "Adjei"
                },
                {
                    "first": "Evans",
                    "initial": "E.",
                    "last": "Kwara"
                },
                {
                    "first": "Daniel",
                    "initial": "D.",
                    "last": "Chandramohan"
                },
                {
                    "first": "Brian",
                    "initial": "B.",
                    "last": "Greenwood"
                },
                {
                    "first": "John",
                    "initial": "J.",
                    "last": "Lusingu"
                },
                {
                    "first": "Samwel",
                    "initial": "S.",
                    "last": "Gesase"
                },
                {
                    "first": "Anangisye",
                    "initial": "A.",
                    "last": "Malabeja"
                },
                {
                    "first": "Omari",
                    "initial": "O.",
                    "last": "Abdul"
                },
                {
                    "first": "Coline",
                    "initial": "C.",
                    "last": "Mahende"
                },
                {
                    "first": "Edwin",
                    "initial": "E.",
                    "last": "Liheluka"
                },
                {
                    "first": "Lincoln",
                    "initial": "L.",
                    "last": "Malle"
                },
                {
                    "first": "Martha",
                    "initial": "M.",
                    "last": "Lemnge"
                },
                {
                    "first": "Thor G.",
                    "initial": "T.G.",
                    "last": "Theander"
                },
                {
                    "first": "Chris",
                    "initial": "C.",
                    "last": "Drakeley"
                },
                {
                    "first": "Daniel",
                    "initial": "D.",
                    "last": "Ansong"
                },
                {
                    "first": "Tsiri",
                    "initial": "T.",
                    "last": "Agbenyega"
                },
                {
                    "first": "Samuel",
                    "initial": "S.",
                    "last": "Adjei"
                },
                {
                    "first": "Harry Owusu",
                    "initial": "H.O.",
                    "last": "Boateng"
                },
                {
                    "first": "Theresa",
                    "initial": "T.",
                    "last": "Rettig"
                },
                {
                    "first": "John",
                    "initial": "J.",
                    "last": "Bawa"
                },
                {
                    "first": "Justice",
                    "initial": "J.",
                    "last": "Sylverken"
                },
                {
                    "first": "David",
                    "initial": "D.",
                    "last": "Sambian"
                },
                {
                    "first": "Anima",
                    "initial": "A.",
                    "last": "Sarfo"
                },
                {
                    "first": "Alex",
                    "initial": "A.",
                    "last": "Agyekum"
                },
                {
                    "first": "Francis",
                    "initial": "F.",
                    "last": "Martinson"
                },
                {
                    "first": "Irving",
                    "initial": "I.",
                    "last": "Hoffman"
                },
                {
                    "first": "Tisungane",
                    "initial": "T.",
                    "last": "Mvalo"
                },
                {
                    "first": "Portia",
                    "initial": "P.",
                    "last": "Kamthunzi"
                },
                {
                    "first": "Rutendo",
                    "initial": "R.",
                    "last": "Nkomo"
                },
                {
                    "first": "Tapiwa",
                    "initial": "T.",
                    "last": "Tembo"
                },
                {
                    "first": "Gerald",
                    "initial": "G.",
                    "last": "Tegha"
                },
                {
                    "first": "Mercy",
                    "initial": "M.",
                    "last": "Tsidya"
                },
                {
                    "first": "Jane",
                    "initial": "J.",
                    "last": "Kilembe"
                },
                {
                    "first": "Chimwemwe",
                    "initial": "C.",
                    "last": "Chawinga"
                },
                {
                    "first": "W. Ripley",
                    "initial": "W.R.",
                    "last": "Ballou"
                },
                {
                    "first": "Joe",
                    "initial": "J.",
                    "last": "Cohen"
                },
                {
                    "first": "Yolanda",
                    "initial": "Y.",
                    "last": "Guerra"
                },
                {
                    "first": "Erik",
                    "initial": "E.",
                    "last": "Jongert"
                },
                {
                    "first": "Didier",
                    "initial": "D.",
                    "last": "Lapierre"
                },
                {
                    "first": "Amanda",
                    "initial": "A.",
                    "last": "Leach"
                },
                {
                    "first": "Marc",
                    "initial": "M.",
                    "last": "Lievens"
                },
                {
                    "first": "Opokua",
                    "initial": "O.",
                    "last": "Ofori-Anyinam"
                },
                {
                    "first": "Aur\u00e9lie",
                    "initial": "A.",
                    "last": "Olivier"
                },
                {
                    "first": "Johan",
                    "initial": "J.",
                    "last": "Vekemans"
                },
                {
                    "first": "Terrell",
                    "initial": "T.",
                    "last": "Carter"
                },
                {
                    "first": "David",
                    "initial": "D.",
                    "last": "Kaslow"
                },
                {
                    "first": "Didier",
                    "initial": "D.",
                    "last": "Leboulleux"
                },
                {
                    "first": "Christian",
                    "initial": "C.",
                    "last": "Loucq"
                },
                {
                    "first": "Afiya",
                    "initial": "A.",
                    "last": "Radford"
                },
                {
                    "first": "Barbara",
                    "initial": "B.",
                    "last": "Savarese"
                },
                {
                    "first": "David",
                    "initial": "D.",
                    "last": "Schellenberg"
                },
                {
                    "first": "Marla",
                    "initial": "M.",
                    "last": "Sillman"
                },
                {
                    "first": "Preeti",
                    "initial": "P.",
                    "last": "Vansadia"
                },
                {
                    "first": "Sara",
                    "initial": "S.",
                    "last": "Mian-McCarthy"
                }
            ],
            "doi": "10.1056/NEJMoa1208394",
            "firstpage": "2284",
            "issn": "00284793",
            "lastpage": "2295",
            "pmid": "23136909",
            "pub_year": 2012,
            "title": "A phase 3 trial of RTS,S/AS01 malaria vaccine in African infants",
            "volume": "367"
        },
        "b0020": {
            "authors": [
                {
                    "first": "Patrick Georges",
                    "initial": "P.G.",
                    "last": "Cech"
                },
                {
                    "first": "Thomas",
                    "initial": "T.",
                    "last": "Aebi"
                },
                {
                    "first": "Mwanajaa Shomari",
                    "initial": "M.S.",
                    "last": "Abdallah"
                },
                {
                    "first": "Maxmillian",
                    "initial": "M.",
                    "last": "Mpina"
                },
                {
                    "first": "Ester Barnabas",
                    "initial": "E.B.",
                    "last": "Machunda"
                },
                {
                    "first": "Nicole",
                    "initial": "N.",
                    "last": "Westerfeld"
                },
                {
                    "first": "Sabine Alexandra",
                    "initial": "S.A.",
                    "last": "Stoffel"
                },
                {
                    "first": "Rinaldo",
                    "initial": "R.",
                    "last": "Zurbriggen"
                },
                {
                    "first": "Gerd",
                    "initial": "G.",
                    "last": "Pluschke"
                },
                {
                    "first": "Marcel",
                    "initial": "M.",
                    "last": "Tanner"
                },
                {
                    "first": "Claudia",
                    "initial": "C.",
                    "last": "Daubenberger"
                },
                {
                    "first": "Blaise",
                    "initial": "B.",
                    "last": "Genton"
                },
                {
                    "first": "Salim",
                    "initial": "S.",
                    "last": "Abdulla"
                }
            ],
            "doi": "10.1371/journal.pone.0022273",
            "issn": "19326203",
            "pmid": "21799810",
            "pub_year": 2011,
            "title": "Virosome-formulated plasmodium falciparum AMA-1 & CSP derived peptides as malaria vaccine: Randomized phase 1b trial in semi-immune adults & children",
            "volume": "6"
        },
        "b0025": {
            "authors": [
                {
                    "first": "Blaise",
                    "initial": "B.",
                    "last": "Genton"
                },
                {
                    "first": "Gerd",
                    "initial": "G.",
                    "last": "Pluschke"
                },
                {
                    "first": "Lukas",
                    "initial": "L.",
                    "last": "Degen"
                },
                {
                    "first": "Andreas R.",
                    "initial": "A.R.",
                    "last": "Kammer"
                },
                {
                    "first": "Nicole",
                    "initial": "N.",
                    "last": "Westerfeld"
                },
                {
                    "first": "Shinji L.",
                    "initial": "S.L.",
                    "last": "Okitsu"
                },
                {
                    "first": "Sandro",
                    "initial": "S.",
                    "last": "Schroller"
                },
                {
                    "first": "Penelope",
                    "initial": "P.",
                    "last": "Vounatsou"
                },
                {
                    "first": "Markus M.",
                    "initial": "M.M.",
                    "last": "Mueller"
                },
                {
                    "first": "Marcel",
                    "initial": "M.",
                    "last": "Tanner"
                },
                {
                    "first": "Rinaldo",
                    "initial": "R.",
                    "last": "Zurbriggen"
                }
            ],
            "doi": "10.1371/journal.pone.0001018",
            "issn": "19326203",
            "pmid": "17925866",
            "pub_year": 2007,
            "title": "A randomized placebo-controlled phase la malaria vaccine trial of two virosome-formulated synthetic peptides in healthy adult volunteers",
            "volume": "2"
        },
        "b0030": {
            "authors": [
                {
                    "first": "Shinji L.",
                    "initial": "S.L.",
                    "last": "Okitsu"
                },
                {
                    "first": "Olivier",
                    "initial": "O.",
                    "last": "Silvie"
                },
                {
                    "first": "Nicole",
                    "initial": "N.",
                    "last": "Westerfeld"
                },
                {
                    "first": "Marija",
                    "initial": "M.",
                    "last": "Curcic"
                },
                {
                    "first": "Andreas R.",
                    "initial": "A.R.",
                    "last": "Kammer"
                },
                {
                    "first": "Markus S.",
                    "initial": "M.S.",
                    "last": "Mueller"
                },
                {
                    "first": "Robert W.",
                    "initial": "R.W.",
                    "last": "Sauerwein"
                },
                {
                    "first": "John A.",
                    "initial": "J.A.",
                    "last": "Robinson"
                },
                {
                    "first": "Blaise",
                    "initial": "B.",
                    "last": "Genton"
                },
                {
                    "first": "Dominique",
                    "initial": "D.",
                    "last": "Mazier"
                },
                {
                    "first": "Rinaldo",
                    "initial": "R.",
                    "last": "Zurbriggen"
                },
                {
                    "first": "Gerd",
                    "initial": "G.",
                    "last": "Pluschke"
                }
            ],
            "doi": "10.1371/journal.pone.0001278",
            "issn": "19326203",
            "pmid": "18060072",
            "pub_year": 2007,
            "title": "A virosomal malaria Peptide vaccine elicits a longlasting sporozoite-inhibitory antibody response in a phase 1a clinical trail",
            "volume": "2"
        },
        "b0035": {
            "authors": [
                {
                    "first": "Mahamadou A.",
                    "initial": "M.A.",
                    "last": "Thera"
                },
                {
                    "first": "Ogobara K.",
                    "initial": "O.K.",
                    "last": "Doumbo"
                },
                {
                    "first": "Drissa",
                    "initial": "D.",
                    "last": "Coulibaly"
                },
                {
                    "first": "Matthew B.",
                    "initial": "M.B.",
                    "last": "Laurens"
                },
                {
                    "first": "Abdoulaye K.",
                    "initial": "A.K.",
                    "last": "Kone"
                },
                {
                    "first": "Ando B.",
                    "initial": "A.B.",
                    "last": "Guindo"
                },
                {
                    "first": "Karim",
                    "initial": "K.",
                    "last": "Traore"
                },
                {
                    "first": "Mady",
                    "initial": "M.",
                    "last": "Sissoko"
                },
                {
                    "first": "Dapa A.",
                    "initial": "D.A.",
                    "last": "Diallo"
                },
                {
                    "first": "Issa",
                    "initial": "I.",
                    "last": "Diarra"
                },
                {
                    "first": "Bourema",
                    "initial": "B.",
                    "last": "Kouriba"
                },
                {
                    "first": "Modibo",
                    "initial": "M.",
                    "last": "Daou"
                },
                {
                    "first": "Amagana",
                    "initial": "A.",
                    "last": "Dolo"
                },
                {
                    "first": "Mounirou",
                    "initial": "M.",
                    "last": "Baby"
                },
                {
                    "first": "Mahamadou S.",
                    "initial": "M.S.",
                    "last": "Sissoko"
                },
                {
                    "first": "Issaka",
                    "initial": "I.",
                    "last": "Sagara"
                },
                {
                    "first": "Amadou",
                    "initial": "A.",
                    "last": "Niangaly"
                },
                {
                    "first": "Idrissa",
                    "initial": "I.",
                    "last": "Traore"
                },
                {
                    "first": "Ally",
                    "initial": "A.",
                    "last": "Olotu"
                },
                {
                    "first": "Olivier",
                    "initial": "O.",
                    "last": "Godeaux"
                },
                {
                    "first": "Amanda",
                    "initial": "A.",
                    "last": "Leach"
                },
                {
                    "first": "Marie Claude",
                    "initial": "M.C.",
                    "last": "Dubois"
                },
                {
                    "first": "W. Ripley",
                    "initial": "W.R.",
                    "last": "Ballou"
                },
                {
                    "first": "Joe",
                    "initial": "J.",
                    "last": "Cohen"
                },
                {
                    "first": "Darby",
                    "initial": "D.",
                    "last": "Thompson"
                },
                {
                    "first": "Tina",
                    "initial": "T.",
                    "last": "Dube"
                },
                {
                    "first": "Lorraine",
                    "initial": "L.",
                    "last": "Soisson"
                },
                {
                    "first": "Carter L.",
                    "initial": "C.L.",
                    "last": "Diggs"
                },
                {
                    "first": "Shannon L.",
                    "initial": "S.L.",
                    "last": "Takala"
                },
                {
                    "first": "Kirsten E.",
                    "initial": "K.E.",
                    "last": "Lyke"
                },
                {
                    "first": "Brent",
                    "initial": "B.",
                    "last": "House"
                },
                {
                    "first": "David E.",
                    "initial": "D.E.",
                    "last": "Lanar"
                },
                {
                    "first": "Sheetij",
                    "initial": "S.",
                    "last": "Dutta"
                },
                {
                    "first": "D. Gray",
                    "initial": "D.G.",
                    "last": "Heppner"
                },
                {
                    "first": "Christopher V.",
                    "initial": "C.V.",
                    "last": "Plowe"
                }
            ],
            "doi": "10.1371/journal.pone.0009041",
            "issn": "19326203",
            "pmid": "20140214",
            "pub_year": 2010,
            "title": "Safety and immunogenicity of an AMA1 malaria vaccine in Malian children: Results of a phase 1 randomized controlled trial",
            "volume": "5"
        },
        "b0040": {
            "authors": [
                {
                    "first": "Mahamadou A.",
                    "initial": "M.A.",
                    "last": "Thera"
                },
                {
                    "first": "Ogobara K.",
                    "initial": "O.K.",
                    "last": "Doumbo"
                },
                {
                    "first": "Drissa",
                    "initial": "D.",
                    "last": "Coulibaly"
                },
                {
                    "first": "Matthew B.",
                    "initial": "M.B.",
                    "last": "Laurens"
                },
                {
                    "first": "Amed",
                    "initial": "A.",
                    "last": "Ouattara"
                },
                {
                    "first": "Abdoulaye K.",
                    "initial": "A.K.",
                    "last": "Kone"
                },
                {
                    "first": "Ando B.",
                    "initial": "A.B.",
                    "last": "Guindo"
                },
                {
                    "first": "Karim",
                    "initial": "K.",
                    "last": "Traore"
                },
                {
                    "first": "Idrissa",
                    "initial": "I.",
                    "last": "Traore"
                },
                {
                    "first": "Bourema",
                    "initial": "B.",
                    "last": "Kouriba"
                },
                {
                    "first": "Dapa A.",
                    "initial": "D.A.",
                    "last": "Diallo"
                },
                {
                    "first": "Issa",
                    "initial": "I.",
                    "last": "Diarra"
                },
                {
                    "first": "Modibo",
                    "initial": "M.",
                    "last": "Daou"
                },
                {
                    "first": "Amagana",
                    "initial": "A.",
                    "last": "Dolo"
                },
                {
                    "first": "Youssouf",
                    "initial": "Y.",
                    "last": "Tolo"
                },
                {
                    "first": "Mahamadou S.",
                    "initial": "M.S.",
                    "last": "Sissoko"
                },
                {
                    "first": "Amadou",
                    "initial": "A.",
                    "last": "Niangaly"
                },
                {
                    "first": "Mady",
                    "initial": "M.",
                    "last": "Sissoko"
                },
                {
                    "first": "Shannon",
                    "initial": "S.",
                    "last": "Takala-Harrison"
                },
                {
                    "first": "Kirsten E.",
                    "initial": "K.E.",
                    "last": "Lyke"
                },
                {
                    "first": "Yukun",
                    "initial": "Y.",
                    "last": "Wu"
                },
                {
                    "first": "William C.",
                    "initial": "W.C.",
                    "last": "Blackwelder"
                },
                {
                    "first": "Olivier",
                    "initial": "O.",
                    "last": "Godeaux"
                },
                {
                    "first": "Johan",
                    "initial": "J.",
                    "last": "Vekemans"
                },
                {
                    "first": "Marie Claude",
                    "initial": "M.C.",
                    "last": "Dubois"
                },
                {
                    "first": "W. Ripley",
                    "initial": "W.R.",
                    "last": "Ballou"
                },
                {
                    "first": "Joe",
                    "initial": "J.",
                    "last": "Cohen"
                },
                {
                    "first": "Darby",
                    "initial": "D.",
                    "last": "Thompson"
                },
                {
                    "first": "Tina",
                    "initial": "T.",
                    "last": "Dube"
                },
                {
                    "first": "Lorraine",
                    "initial": "L.",
                    "last": "Soisson"
                },
                {
                    "first": "Carter L.",
                    "initial": "C.L.",
                    "last": "Diggs"
                },
                {
                    "first": "Brent",
                    "initial": "B.",
                    "last": "House"
                },
                {
                    "first": "David E.",
                    "initial": "D.E.",
                    "last": "Lanar"
                },
                {
                    "first": "Sheetij",
                    "initial": "S.",
                    "last": "Dutta"
                },
                {
                    "first": "D. Gray",
                    "initial": "D.G.",
                    "last": "Heppner"
                },
                {
                    "first": "Christopher V.",
                    "initial": "C.V.",
                    "last": "Plowe"
                }
            ],
            "doi": "10.1056/NEJMoa1008115",
            "firstpage": "1004",
            "issn": "00284793",
            "lastpage": "1013",
            "pub_year": 2011,
            "title": "A field trial to assess a blood-stage malaria vaccine",
            "volume": "365"
        },
        "b0045": {
            "authors": [
                {
                    "first": "Adrian V.S.",
                    "initial": "A.V.S.",
                    "last": "Hill"
                }
            ],
            "doi": "10.1098/rstb.2011.0091",
            "firstpage": "2806",
            "issn": "09628436",
            "lastpage": "2814",
            "pub_year": 2011,
            "title": "Vaccines against malaria",
            "volume": "366"
        },
        "b0050": {
            "authors": [
                {
                    "first": null,
                    "initial": null,
                    "last": "The malERA Consultative Group on Vaccines"
                }
            ],
            "doi": "10.1371/journal.pmed.1000398",
            "issn": "15491277",
            "pmid": "21311586",
            "pub_year": 2011,
            "title": "A research agenda for malaria eradication: Vaccines",
            "volume": "8"
        },
        "b0055": {
            "authors": [
                {
                    "first": "G.",
                    "initial": "G.",
                    "last": "Pradel"
                }
            ],
            "doi": "10.1017/S0031182007003381",
            "firstpage": "1911",
            "issn": "00311820",
            "lastpage": "1929",
            "pmid": "17714601",
            "pub_year": 2007,
            "title": "Proteins of the malaria parasite sexual stages: Expression, function and potential for transmission blocking strategies",
            "volume": "134"
        },
        "b0060": {
            "authors": [
                {
                    "first": "Arno N.",
                    "initial": "A.N.",
                    "last": "Vermeulen"
                },
                {
                    "first": "Thivi",
                    "initial": "T.",
                    "last": "Ponnudurai"
                },
                {
                    "first": "Pieter J.A.",
                    "initial": "P.J.A.",
                    "last": "Beckers"
                },
                {
                    "first": "Jan Peter",
                    "initial": "J.P.",
                    "last": "Verhave"
                },
                {
                    "first": "Mari A.",
                    "initial": "M.A.",
                    "last": "Smits"
                },
                {
                    "first": "Joseph H.E.Th",
                    "initial": "J.H.E.T.",
                    "last": "Meuwissen"
                }
            ],
            "doi": "10.1084/jem.162.5.1460",
            "firstpage": "1460",
            "issn": "00221007",
            "lastpage": "1476",
            "pmid": "2865324",
            "pub_year": 1985,
            "title": "Sequential expression of antigens on sexual stages of plasmodium falciparum accessible to transmission-blocking antibodies in the mosquito",
            "volume": "162"
        },
        "b0065": {
            "authors": [
                {
                    "first": "David C.",
                    "initial": "D.C.",
                    "last": "Kaslow"
                },
                {
                    "first": "Isabella A.",
                    "initial": "I.A.",
                    "last": "Quakyi"
                },
                {
                    "first": "Chiang",
                    "initial": "C.",
                    "last": "Syin"
                },
                {
                    "first": "Michael G.",
                    "initial": "M.G.",
                    "last": "Raum"
                },
                {
                    "first": "David B.",
                    "initial": "D.B.",
                    "last": "Keister"
                },
                {
                    "first": "John E.",
                    "initial": "J.E.",
                    "last": "Coligan"
                },
                {
                    "first": "Thomas F.",
                    "initial": "T.F.",
                    "last": "McCutchan"
                },
                {
                    "first": "Louis H.",
                    "initial": "L.H.",
                    "last": "Miller"
                }
            ],
            "doi": "10.1038/333074a0",
            "firstpage": "74",
            "issn": "00280836",
            "lastpage": "76",
            "pmid": "3283563",
            "pub_year": 1988,
            "title": "A vaccine candidate from the sexual stage of human malaria that contains EGF-like domains",
            "volume": "333"
        },
        "b0070": {
            "authors": [
                {
                    "first": "John",
                    "initial": "J.",
                    "last": "Samuelson"
                },
                {
                    "first": "Sulagna",
                    "initial": "S.",
                    "last": "Banerjee"
                },
                {
                    "first": "Paula",
                    "initial": "P.",
                    "last": "Magnelli"
                },
                {
                    "first": "Jike",
                    "initial": "J.",
                    "last": "Cui"
                },
                {
                    "first": "Daniel J.",
                    "initial": "D.J.",
                    "last": "Kelleher"
                },
                {
                    "first": "Reid",
                    "initial": "R.",
                    "last": "Gilmore"
                },
                {
                    "first": "Phillips W.",
                    "initial": "P.W.",
                    "last": "Robbins"
                }
            ],
            "doi": "10.1073/pnas.0409460102",
            "firstpage": "1548",
            "issn": "00278424",
            "lastpage": "1553",
            "pmid": "15665075",
            "pub_year": 2005,
            "title": "The diversity of dolichol-linked precursors to Asn-linked glycans likely results from secondary loss of sets glycosyltranferases",
            "volume": "102"
        },
        "b0075": {
            "authors": [
                {
                    "first": "Philip J.",
                    "initial": "P.J.",
                    "last": "Barr"
                },
                {
                    "first": "Kim M.",
                    "initial": "K.M.",
                    "last": "Green"
                },
                {
                    "first": "Helen L.",
                    "initial": "H.L.",
                    "last": "Gibson"
                },
                {
                    "first": "Ian C.",
                    "initial": "I.C.",
                    "last": "Bathurst"
                },
                {
                    "first": "Isabella A.",
                    "initial": "I.A.",
                    "last": "Quakyi"
                },
                {
                    "first": "David C.",
                    "initial": "D.C.",
                    "last": "Kaslow"
                }
            ],
            "doi": "10.1084/jem.174.5.1203",
            "firstpage": "1203",
            "issn": "00221007",
            "lastpage": "1208",
            "pmid": "1940798",
            "pub_year": 1991,
            "title": "Recombinant pfs25 protein of plasmocdium falciparum elicits malaria transmission-blocking immunity in experimental animals",
            "volume": "174"
        },
        "b0080": {
            "authors": [
                {
                    "first": "D. C.",
                    "initial": "D.C.",
                    "last": "Kaslow"
                },
                {
                    "first": "I. C.",
                    "initial": "I.C.",
                    "last": "Bathurst"
                },
                {
                    "first": "T.",
                    "initial": "T.",
                    "last": "Lensen"
                },
                {
                    "first": "T.",
                    "initial": "T.",
                    "last": "Ponnudurai"
                },
                {
                    "first": "P. J.",
                    "initial": "P.J.",
                    "last": "Barr"
                },
                {
                    "first": "D. B.",
                    "initial": "D.B.",
                    "last": "Keister"
                }
            ],
            "firstpage": "5576",
            "issn": "00199567",
            "lastpage": "5580",
            "pmid": "7960139",
            "pub_year": 1994,
            "title": "Saccharomyces cerevisiae recombinant Pfs25 adsorbed to alum elicits antibodies that block transmission of Plasmodium falciparum",
            "volume": "62"
        },
        "b0085": {
            "authors": [
                {
                    "first": "Joanna",
                    "initial": "J.",
                    "last": "Kubler-Kielb"
                },
                {
                    "first": "Fathy",
                    "initial": "F.",
                    "last": "Majadly"
                },
                {
                    "first": "Yimin",
                    "initial": "Y.",
                    "last": "Wu"
                },
                {
                    "first": "David L.",
                    "initial": "D.L.",
                    "last": "Narum"
                },
                {
                    "first": "Chunyan",
                    "initial": "C.",
                    "last": "Guo"
                },
                {
                    "first": "Louis H.",
                    "initial": "L.H.",
                    "last": "Miller"
                },
                {
                    "first": "Joseph",
                    "initial": "J.",
                    "last": "Shiloach"
                },
                {
                    "first": "John B.",
                    "initial": "J.B.",
                    "last": "Robbins"
                },
                {
                    "first": "Rachel",
                    "initial": "R.",
                    "last": "Schneerson"
                }
            ],
            "doi": "10.1073/pnas.0609885104",
            "firstpage": "293",
            "issn": "00278424",
            "lastpage": "298",
            "pmid": "17190797",
            "pub_year": 2007,
            "title": "Long-lasting and transmission-blocking activity of antibodies to Plasmodium falciparum elicited in mice by protein conjugates of Pfs25",
            "volume": "104"
        },
        "b0090": {
            "authors": [
                {
                    "first": "Kazutoyo",
                    "initial": "K.",
                    "last": "Miura"
                },
                {
                    "first": "David B.",
                    "initial": "D.B.",
                    "last": "Keister"
                },
                {
                    "first": "Olga V.",
                    "initial": "O.V.",
                    "last": "Muratova"
                },
                {
                    "first": "Jetsumon",
                    "initial": "J.",
                    "last": "Sattabongkot"
                },
                {
                    "first": "Carole A.",
                    "initial": "C.A.",
                    "last": "Long"
                },
                {
                    "first": "Allan",
                    "initial": "A.",
                    "last": "Saul"
                }
            ],
            "doi": "10.1186/1475-2875-6-107",
            "issn": "14752875",
            "pmid": "17686163",
            "pub_year": 2007,
            "title": "Transmission-blocking activity induced by malaria vaccine candidates Pfs25/Pvs25 is a direct and predictable function of antibody titer",
            "volume": "6"
        },
        "b0095": {
            "authors": [
                {
                    "first": "Feng",
                    "initial": "F.",
                    "last": "Qian"
                },
                {
                    "first": "Kelly M.",
                    "initial": "K.M.",
                    "last": "Rausch"
                },
                {
                    "first": "Olga",
                    "initial": "O.",
                    "last": "Muratova"
                },
                {
                    "first": "Hong",
                    "initial": "H.",
                    "last": "Zhou"
                },
                {
                    "first": "Guanhong",
                    "initial": "G.",
                    "last": "Song"
                },
                {
                    "first": "Ababacar",
                    "initial": "A.",
                    "last": "Diouf"
                },
                {
                    "first": "Lynn",
                    "initial": "L.",
                    "last": "Lambert"
                },
                {
                    "first": "David L.",
                    "initial": "D.L.",
                    "last": "Narum"
                },
                {
                    "first": "Yimin",
                    "initial": "Y.",
                    "last": "Wu"
                },
                {
                    "first": "Allan",
                    "initial": "A.",
                    "last": "Saul"
                },
                {
                    "first": "Louis H.",
                    "initial": "L.H.",
                    "last": "Miller"
                },
                {
                    "first": "Carole A.",
                    "initial": "C.A.",
                    "last": "Long"
                },
                {
                    "first": "Gregory E.D.",
                    "initial": "G.E.D.",
                    "last": "Mullen"
                }
            ],
            "doi": "10.1016/j.vaccine.2008.03.005",
            "firstpage": "2521",
            "issn": "0264410X",
            "lastpage": "2527",
            "pmid": "18423804",
            "pub_year": 2008,
            "title": "Addition of CpG ODN to recombinant Pseudomonas aeruginosa ExoProtein A conjugates of AMA1 and Pfs25 greatly increases the number of responders",
            "volume": "26"
        },
        "b0100": {
            "authors": [
                {
                    "first": "Feng",
                    "initial": "F.",
                    "last": "Qian"
                },
                {
                    "first": "Yimin",
                    "initial": "Y.",
                    "last": "Wu"
                },
                {
                    "first": "Olga",
                    "initial": "O.",
                    "last": "Muratova"
                },
                {
                    "first": "Hong",
                    "initial": "H.",
                    "last": "Zhou"
                },
                {
                    "first": "Gelu",
                    "initial": "G.",
                    "last": "Dobrescu"
                },
                {
                    "first": "Peter",
                    "initial": "P.",
                    "last": "Duggan"
                },
                {
                    "first": "Lambert",
                    "initial": "L.",
                    "last": "Lynn"
                },
                {
                    "first": "Guanhong",
                    "initial": "G.",
                    "last": "Song"
                },
                {
                    "first": "Yanling",
                    "initial": "Y.",
                    "last": "Zhang"
                },
                {
                    "first": "Karine",
                    "initial": "K.",
                    "last": "Reiter"
                },
                {
                    "first": "Nicholas",
                    "initial": "N.",
                    "last": "MacDonald"
                },
                {
                    "first": "David L.",
                    "initial": "D.L.",
                    "last": "Narum"
                },
                {
                    "first": "Carole A.",
                    "initial": "C.A.",
                    "last": "Long"
                },
                {
                    "first": "Louis H.",
                    "initial": "L.H.",
                    "last": "Miller"
                },
                {
                    "first": "Allan",
                    "initial": "A.",
                    "last": "Saul"
                },
                {
                    "first": "Gregory E.D.",
                    "initial": "G.E.D.",
                    "last": "Mullen"
                }
            ],
            "doi": "10.1016/j.vaccine.2007.02.073",
            "firstpage": "3923",
            "issn": "0264410X",
            "lastpage": "3933",
            "pmid": "17428587",
            "pub_year": 2007,
            "title": "Conjugating recombinant proteins to Pseudomonas aeruginosa ExoProtein A: A strategy for enhancing immunogenicity of malaria vaccine candidates",
            "volume": "25"
        },
        "b0105": {
            "authors": [
                {
                    "first": "Yimin",
                    "initial": "Y.",
                    "last": "Wu"
                },
                {
                    "first": "Ruth D.",
                    "initial": "R.D.",
                    "last": "Ellis"
                },
                {
                    "first": "Donna",
                    "initial": "D.",
                    "last": "Shaffer"
                },
                {
                    "first": "Erica",
                    "initial": "E.",
                    "last": "Fontes"
                },
                {
                    "first": "Elissa M.",
                    "initial": "E.M.",
                    "last": "Malkin"
                },
                {
                    "first": "Siddhartha",
                    "initial": "S.",
                    "last": "Mahanty"
                },
                {
                    "first": "Michael P.",
                    "initial": "M.P.",
                    "last": "Fay"
                },
                {
                    "first": "David",
                    "initial": "D.",
                    "last": "Narum"
                },
                {
                    "first": "Kelly",
                    "initial": "K.",
                    "last": "Rausch"
                },
                {
                    "first": "Aaron P.",
                    "initial": "A.P.",
                    "last": "Miles"
                },
                {
                    "first": "Joan",
                    "initial": "J.",
                    "last": "Aebig"
                },
                {
                    "first": "Andrew",
                    "initial": "A.",
                    "last": "Orcutt"
                },
                {
                    "first": "Olga",
                    "initial": "O.",
                    "last": "Muratova"
                },
                {
                    "first": "Guanhong",
                    "initial": "G.",
                    "last": "Song"
                },
                {
                    "first": "Lynn",
                    "initial": "L.",
                    "last": "Lambert"
                },
                {
                    "first": "Daming",
                    "initial": "D.",
                    "last": "Zhu"
                },
                {
                    "first": "Kazutoyo",
                    "initial": "K.",
                    "last": "Miura"
                },
                {
                    "first": "Carole",
                    "initial": "C.",
                    "last": "Long"
                },
                {
                    "first": "Allan",
                    "initial": "A.",
                    "last": "Saul"
                },
                {
                    "first": "Louis H.",
                    "initial": "L.H.",
                    "last": "Miller"
                },
                {
                    "first": "Anna P.",
                    "initial": "A.P.",
                    "last": "Durbin"
                }
            ],
            "doi": "10.1371/journal.pone.0002636",
            "issn": "19326203",
            "pmid": "18612426",
            "pub_year": 2008,
            "title": "Phase 1 trial of malaria transmission blocking vaccine candidates Pfs25 and Pvs 25 formulated with montanide ISA 51",
            "volume": "3"
        },
        "b0110": {
            "authors": [
                {
                    "first": "Yimin",
                    "initial": "Y.",
                    "last": "Wu"
                },
                {
                    "first": "Craig",
                    "initial": "C.",
                    "last": "Przysiecki"
                },
                {
                    "first": "Elizabeth",
                    "initial": "E.",
                    "last": "Flanagan"
                },
                {
                    "first": "Sheila N.",
                    "initial": "S.N.",
                    "last": "Bello-Irizarry"
                },
                {
                    "first": "Roxana",
                    "initial": "R.",
                    "last": "Ionescu"
                },
                {
                    "first": "Olga",
                    "initial": "O.",
                    "last": "Muratova"
                },
                {
                    "first": "Gelu",
                    "initial": "G.",
                    "last": "Dobrescu"
                },
                {
                    "first": "Lyon",
                    "initial": "L.",
                    "last": "Lambert"
                },
                {
                    "first": "David",
                    "initial": "D.",
                    "last": "Keister"
                },
                {
                    "first": "Yvette",
                    "initial": "Y.",
                    "last": "Rippeon"
                },
                {
                    "first": "Carole A.",
                    "initial": "C.A.",
                    "last": "Long"
                },
                {
                    "first": "Li",
                    "initial": "L.",
                    "last": "Shi"
                },
                {
                    "first": "Michael",
                    "initial": "M.",
                    "last": "Caulfield"
                },
                {
                    "first": "Alan",
                    "initial": "A.",
                    "last": "Shaw"
                },
                {
                    "first": "Allan",
                    "initial": "A.",
                    "last": "Saul"
                },
                {
                    "first": "John",
                    "initial": "J.",
                    "last": "Shiver"
                },
                {
                    "first": "Louis H.",
                    "initial": "L.H.",
                    "last": "Miller"
                }
            ],
            "doi": "10.1073/pnas.0608545103",
            "firstpage": "18243",
            "issn": "00278424",
            "lastpage": "18248",
            "pmid": "17110440",
            "pub_year": 2006,
            "title": "Sustained high-titer antibody responses induced by conjugating a malarial vaccine candidate to outer-membrane protein complex",
            "volume": "103"
        },
        "b0115": {
            "authors": [
                {
                    "first": "Lanling",
                    "initial": "L.",
                    "last": "Zou"
                },
                {
                    "first": "Aaron P.",
                    "initial": "A.P.",
                    "last": "Miles"
                },
                {
                    "first": "Jin",
                    "initial": "J.",
                    "last": "Wang"
                },
                {
                    "first": "Anthony W.",
                    "initial": "A.W.",
                    "last": "Stowers"
                }
            ],
            "doi": "10.1016/S0264-410X(02)00701-6",
            "firstpage": "1650",
            "issn": "0264410X",
            "lastpage": "1657",
            "pmid": "12639486",
            "pub_year": 2003,
            "title": "Expression of malaria transmission-blocking vaccine antigen Pfs25 in Pichia pastoris for use in human clinical trials",
            "volume": "21"
        },
        "b0120": {
            "authors": [
                {
                    "first": "Chiawei W.",
                    "initial": "C.W.",
                    "last": "Tsai"
                },
                {
                    "first": "Peter F.",
                    "initial": "P.F.",
                    "last": "Duggan"
                },
                {
                    "first": "Richard L.",
                    "initial": "R.L.",
                    "last": "Shimp"
                },
                {
                    "first": "Louis H.",
                    "initial": "L.H.",
                    "last": "Miller"
                },
                {
                    "first": "David L.",
                    "initial": "D.L.",
                    "last": "Narum"
                }
            ],
            "doi": "10.1016/j.jbiotec.2005.08.025",
            "firstpage": "458",
            "issn": "01681656",
            "lastpage": "470",
            "pmid": "16274825",
            "pub_year": 2006,
            "title": "Overproduction of Pichia pastoris or Plasmodium falciparum protein disulfide isomerase affects expression, folding and O-linked glycosylation of a malaria vaccine candidate expressed in P. pastoris",
            "volume": "121"
        },
        "b0125": null,
        "b0130": {
            "authors": [
                {
                    "first": "Edward P.",
                    "initial": "E.P.",
                    "last": "Rybicki"
                }
            ],
            "doi": "10.1111/j.1467-7652.2010.00507.x",
            "firstpage": "620",
            "issn": "14677644",
            "lastpage": "637",
            "pmid": "20233333",
            "pub_year": 2010,
            "title": "Plant-made vaccines for humans and animals",
            "volume": "8"
        },
        "b0135": {
            "authors": [
                {
                    "first": "Vidadi",
                    "initial": "V.",
                    "last": "Yusibov"
                },
                {
                    "first": "Stephen J.",
                    "initial": "S.J.",
                    "last": "Streatfield"
                },
                {
                    "first": "Natasha",
                    "initial": "N.",
                    "last": "Kushnir"
                }
            ],
            "doi": "10.4161/hv.7.3.14207",
            "firstpage": "313",
            "issn": "15548600",
            "lastpage": "321",
            "pmid": "21346417",
            "pub_year": 2011,
            "title": "Clinical development of plant-produced recombinant pharmaceuticals: Vaccines, antibodies and beyond",
            "volume": "7"
        },
        "b0140": {
            "authors": [
                {
                    "first": "Christine E.",
                    "initial": "C.E.",
                    "last": "Farrance"
                },
                {
                    "first": "Jessica A.",
                    "initial": "J.A.",
                    "last": "Chichester"
                },
                {
                    "first": "Konstantin",
                    "initial": "K.",
                    "last": "Musiychuk"
                },
                {
                    "first": "Moneim",
                    "initial": "M.",
                    "last": "Shamloul"
                },
                {
                    "first": "Amy",
                    "initial": "A.",
                    "last": "Rhee"
                },
                {
                    "first": "Slobodanka D.",
                    "initial": "S.D.",
                    "last": "Manceva"
                },
                {
                    "first": "R. Mark",
                    "initial": "R.M.",
                    "last": "Jones"
                },
                {
                    "first": "Tarlan",
                    "initial": "T.",
                    "last": "Mamedov"
                },
                {
                    "first": "Satish",
                    "initial": "S.",
                    "last": "Sharma"
                },
                {
                    "first": "Vadim",
                    "initial": "V.",
                    "last": "Mett"
                },
                {
                    "first": "Stephen J.",
                    "initial": "S.J.",
                    "last": "Streatfield"
                },
                {
                    "first": "Will",
                    "initial": "W.",
                    "last": "Roeffen"
                },
                {
                    "first": "Marga",
                    "initial": "M.",
                    "last": "Van De Vegte-Bolmer"
                },
                {
                    "first": "Robert W.",
                    "initial": "R.W.",
                    "last": "Sauerwein"
                },
                {
                    "first": "Yimin",
                    "initial": "Y.",
                    "last": "Wu"
                },
                {
                    "first": "Olga",
                    "initial": "O.",
                    "last": "Muratova"
                },
                {
                    "first": "Louis",
                    "initial": "L.",
                    "last": "Miller"
                },
                {
                    "first": "Patrick",
                    "initial": "P.",
                    "last": "Duffy"
                },
                {
                    "first": "Robert",
                    "initial": "R.",
                    "last": "Sinden"
                },
                {
                    "first": "Vidadi",
                    "initial": "V.",
                    "last": "Yusibov"
                }
            ],
            "doi": "10.4161/hv.7.0.14588",
            "firstpage": "191",
            "issn": "15548600",
            "lastpage": "198",
            "pmid": "21266847",
            "pub_year": 2011,
            "title": "Antibodies to plant-produced Plasmodium falciparum sexual stage protein Pfs25 exhibit transmission blocking activity",
            "volume": "7"
        },
        "b0145": {
            "authors": [
                {
                    "first": "R. Mark",
                    "initial": "R.M.",
                    "last": "Jones"
                },
                {
                    "first": "Jessica A.",
                    "initial": "J.A.",
                    "last": "Chichester"
                },
                {
                    "first": "Slobodanka",
                    "initial": "S.",
                    "last": "Manceva"
                },
                {
                    "first": "Sandra K.",
                    "initial": "S.K.",
                    "last": "Gibbs"
                },
                {
                    "first": "Konstantin",
                    "initial": "K.",
                    "last": "Musiychuk"
                },
                {
                    "first": "Moneim",
                    "initial": "M.",
                    "last": "Shamloul"
                },
                {
                    "first": "Joey",
                    "initial": "J.",
                    "last": "Norikane"
                },
                {
                    "first": "Stephen J.",
                    "initial": "S.J.",
                    "last": "Streatfield"
                },
                {
                    "first": "Marga",
                    "initial": "M.",
                    "last": "Van De Vegte-Bolmer"
                },
                {
                    "first": "Will",
                    "initial": "W.",
                    "last": "Roeffen"
                },
                {
                    "first": "Robert W.",
                    "initial": "R.W.",
                    "last": "Sauerwein"
                },
                {
                    "first": "Vidadi",
                    "initial": "V.",
                    "last": "Yusibov"
                }
            ],
            "doi": "10.4161/hv.34366",
            "firstpage": "124",
            "issn": "21645515",
            "lastpage": "132",
            "pmid": "25483525",
            "pub_year": 2015,
            "title": "A novel plant-produced Pfs25 fusion subunit vaccine induces long-lasting transmission blocking antibody responses",
            "volume": "11"
        },
        "b0150": {
            "authors": [
                {
                    "first": "Elizabeth V.L.",
                    "initial": "E.V.L.",
                    "last": "Grgacic"
                },
                {
                    "first": "David A.",
                    "initial": "D.A.",
                    "last": "Anderson"
                }
            ],
            "doi": "10.1016/j.ymeth.2006.07.018",
            "firstpage": "60",
            "issn": "10462023",
            "lastpage": "65",
            "pmid": "16997714",
            "pub_year": 2006,
            "title": "Virus-like particles: Passport to immune recognition",
            "volume": "40"
        },
        "b0155": {
            "authors": [
                {
                    "first": "Konstantin",
                    "initial": "K.",
                    "last": "Musiychuk"
                },
                {
                    "first": "Natalie",
                    "initial": "N.",
                    "last": "Stephenson"
                },
                {
                    "first": "Hong",
                    "initial": "H.",
                    "last": "Bi"
                },
                {
                    "first": "Christine E.",
                    "initial": "C.E.",
                    "last": "Farrance"
                },
                {
                    "first": "Goran",
                    "initial": "G.",
                    "last": "Orozovic"
                },
                {
                    "first": "Maria",
                    "initial": "M.",
                    "last": "Brodelius"
                },
                {
                    "first": "Peter",
                    "initial": "P.",
                    "last": "Brodelius"
                },
                {
                    "first": "April",
                    "initial": "A.",
                    "last": "Horsey"
                },
                {
                    "first": "Natalia",
                    "initial": "N.",
                    "last": "Ugulava"
                },
                {
                    "first": "Abdel Moneim",
                    "initial": "A.M.",
                    "last": "Shamloul"
                },
                {
                    "first": "Vadim",
                    "initial": "V.",
                    "last": "Mett"
                },
                {
                    "first": "Shailaja",
                    "initial": "S.",
                    "last": "Rabindran"
                },
                {
                    "first": "Stephen J.",
                    "initial": "S.J.",
                    "last": "Streatfield"
                },
                {
                    "first": "Vidadi",
                    "initial": "V.",
                    "last": "Yusibov"
                }
            ],
            "firstpage": "19",
            "issn": "17502659",
            "lastpage": "25",
            "pmid": "19453476",
            "pub_year": 2007,
            "title": "A launch vector for the production of vaccine antigens in plants.",
            "volume": "1"
        },
        "b0160": {
            "authors": [
                {
                    "first": "R. Mark",
                    "initial": "R.M.",
                    "last": "Jones"
                },
                {
                    "first": "Jessica A.",
                    "initial": "J.A.",
                    "last": "Chichester"
                },
                {
                    "first": "Vadim",
                    "initial": "V.",
                    "last": "Mett"
                },
                {
                    "first": "Jennifer",
                    "initial": "J.",
                    "last": "Jaje"
                },
                {
                    "first": "Stephen",
                    "initial": "S.",
                    "last": "Tottey"
                },
                {
                    "first": "Slobodanka",
                    "initial": "S.",
                    "last": "Manceva"
                },
                {
                    "first": "Louis J.",
                    "initial": "L.J.",
                    "last": "Casta"
                },
                {
                    "first": "Sandra K.",
                    "initial": "S.K.",
                    "last": "Gibbs"
                },
                {
                    "first": "Konstantin",
                    "initial": "K.",
                    "last": "Musiychuk"
                },
                {
                    "first": "Moneim",
                    "initial": "M.",
                    "last": "Shamloul"
                },
                {
                    "first": "Joey",
                    "initial": "J.",
                    "last": "Norikane"
                },
                {
                    "first": "Valentina",
                    "initial": "V.",
                    "last": "Mett"
                },
                {
                    "first": "Stephen J.",
                    "initial": "S.J.",
                    "last": "Streatfield"
                },
                {
                    "first": "Marga",
                    "initial": "M.",
                    "last": "Van De Vegte-Bolmer"
                },
                {
                    "first": "Will",
                    "initial": "W.",
                    "last": "Roeffen"
                },
                {
                    "first": "Robert W.",
                    "initial": "R.W.",
                    "last": "Sauerwein"
                },
                {
                    "first": "Vidadi",
                    "initial": "V.",
                    "last": "Yusibov"
                }
            ],
            "doi": "10.1371/journal.pone.0079538",
            "issn": "19326203",
            "pmid": "24260245",
            "pub_year": 2013,
            "title": "A plant-produced Pfs25 VLP malaria vaccine candidate induces persistent transmission blocking antibodies against plasmodium falciparum in immunized mice",
            "volume": "8"
        },
        "b0165": {
            "authors": [
                {
                    "first": "Kazutoyo",
                    "initial": "K.",
                    "last": "Miura"
                },
                {
                    "first": "Bingbing",
                    "initial": "B.",
                    "last": "Deng"
                },
                {
                    "first": "Gregory",
                    "initial": "G.",
                    "last": "Tullo"
                },
                {
                    "first": "Ababacar",
                    "initial": "A.",
                    "last": "Diouf"
                },
                {
                    "first": "Samuel E.",
                    "initial": "S.E.",
                    "last": "Moretz"
                },
                {
                    "first": "Emily",
                    "initial": "E.",
                    "last": "Locke"
                },
                {
                    "first": "Merribeth",
                    "initial": "M.",
                    "last": "Morin"
                },
                {
                    "first": "Michael P.",
                    "initial": "M.P.",
                    "last": "Fay"
                },
                {
                    "first": "Carole A.",
                    "initial": "C.A.",
                    "last": "Long"
                }
            ],
            "doi": "10.1371/journal.pone.0057909",
            "issn": "19326203",
            "pmid": "23483940",
            "pub_year": 2013,
            "title": "Qualification of Standard Membrane-Feeding Assay with Plasmodium falciparum Malaria and Potential Improvements for Future Assays",
            "volume": "8"
        },
        "b0170": {
            "authors": [
                {
                    "first": "Kazutoyo",
                    "initial": "K.",
                    "last": "Miura"
                },
                {
                    "first": "Eizo",
                    "initial": "E.",
                    "last": "Takashima"
                },
                {
                    "first": "Bingbing",
                    "initial": "B.",
                    "last": "Deng"
                },
                {
                    "first": "Gregory",
                    "initial": "G.",
                    "last": "Tullo"
                },
                {
                    "first": "Ababacar",
                    "initial": "A.",
                    "last": "Diouf"
                },
                {
                    "first": "Samuel E.",
                    "initial": "S.E.",
                    "last": "Moretz"
                },
                {
                    "first": "Daria",
                    "initial": "D.",
                    "last": "Nikolaeva"
                },
                {
                    "first": "Mahamadou",
                    "initial": "M.",
                    "last": "Diakite"
                },
                {
                    "first": "Rick M.",
                    "initial": "R.M.",
                    "last": "Fairhurst"
                },
                {
                    "first": "Michael P.",
                    "initial": "M.P.",
                    "last": "Fay"
                },
                {
                    "first": "Carole A.",
                    "initial": "C.A.",
                    "last": "Long"
                },
                {
                    "first": "Takafumi",
                    "initial": "T.",
                    "last": "Tsuboi"
                }
            ],
            "doi": "10.1128/IAI.01056-13",
            "firstpage": "4377",
            "issn": "00199567",
            "lastpage": "4382",
            "pmid": "24042109",
            "pub_year": 2013,
            "title": "Functional comparison of plasmodium falciparum transmission-blocking vaccine candidates by the standard membrane-feeding assay",
            "volume": "81"
        }
    },
    "body_text": [
        {
            "endOffset": 28587,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Materials and methods"
                }
            ],
            "refoffsets": {
                "b0165": {
                    "endOffset": 28586,
                    "startOffset": 28582
                }
            },
            "secId": "s0040",
            "sentence": "TRA of the Pfs25 VLP-FhCMB vaccine-induced anti-Pfs25 antibody was measured by the SMFA, by evaluating the development of oocysts in laboratory-reared mosquitos fed IgG antibodies purified from serum, mixed with a red blood cell suspension containing cultured malaria parasites [33].",
            "startOffset": 28304,
            "title": "Immunogenicity assessments"
        },
        {
            "endOffset": 16082,
            "parents": [],
            "refoffsets": {
                "b0050": {
                    "endOffset": 16081,
                    "startOffset": 16077
                }
            },
            "secId": "s0005",
            "sentence": "In 2011, the Malaria Eradication Research Agenda Consultative Group on Vaccines set as a core goal that any malaria vaccine program needs to reduce transmission as well as morbidity [10].",
            "startOffset": 15895,
            "title": "Introduction"
        },
        {
            "endOffset": 18790,
            "parents": [],
            "refoffsets": {
                "b0160": {
                    "endOffset": 18709,
                    "startOffset": 18705
                }
            },
            "secId": "s0005",
            "sentence": "Immunization of mice with one or two doses of this vaccine candidate adjuvanted with Alhydrogel\u00ae induced serum antibodies with complete TB activity persisting through the six-month study period [32], supporting the evaluation of Pfs25-CP VLP as a potential malaria TBV candidate.",
            "startOffset": 18511,
            "title": "Introduction"
        },
        {
            "endOffset": 21200,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Materials and methods"
                }
            ],
            "secId": "s0020",
            "sentence": "The drug product contained 400 \u00b5g of total protein per mL in an aqueous formulation containing 50 mM sodium phosphate for IM administration and was aseptically filled and packaged at Walter Reed Army Institute of Research (WRAIR) Pilot Bioproduction Facility (Silver Spring, MD).",
            "startOffset": 20921,
            "title": "Vaccine"
        },
        {
            "endOffset": 18050,
            "parents": [],
            "refoffsets": {
                "b0130": {
                    "endOffset": 17979,
                    "startOffset": 17972
                },
                "b0135": {
                    "endOffset": 17979,
                    "startOffset": 17972
                },
                "b0140": {
                    "endOffset": 18049,
                    "startOffset": 18042
                },
                "b0145": {
                    "endOffset": 18049,
                    "startOffset": 18042
                }
            },
            "secId": "s0005",
            "sentence": "During the last two decades, several groups have demonstrated the potential of plants as a safe, cost-effective and highly scalable platform for production of recombinant vaccine antigens and therapeutic proteins [26,27], including variants of the soluble, full-length Pfs25 antigen [28,29].",
            "startOffset": 17759,
            "title": "Introduction"
        },
        {
            "endOffset": 34649,
            "parents": [
                {
                    "id": "s0050",
                    "title": "Results"
                }
            ],
            "secId": "s0060",
            "sentence": "Treatment-Emergent AEs occurring during the study period are summarized in Table 2.",
            "startOffset": 34566,
            "title": "Safety and reactogenicity"
        },
        {
            "endOffset": 39148,
            "parents": [
                {
                    "id": "s0050",
                    "title": "Results"
                }
            ],
            "secId": "s0060",
            "sentence": "Local solicited Treatment-Emergent AEs (injection site reactions) are summarized by event term and severity in Table 3.",
            "startOffset": 39029,
            "title": "Safety and reactogenicity"
        },
        {
            "endOffset": 37575,
            "parents": [
                {
                    "id": "s0050",
                    "title": "Results"
                }
            ],
            "secId": "s0060",
            "sentence": "Within the 28 days after each of the three vaccinations, no more than one subject reported a specific Treatment-Emergent AE that was considered Grade 2 (Supplementary material, Table S1).",
            "startOffset": 37388,
            "title": "Safety and reactogenicity"
        },
        {
            "endOffset": 37387,
            "parents": [
                {
                    "id": "s0050",
                    "title": "Results"
                }
            ],
            "secId": "s0060",
            "sentence": "This pattern was generally consistent during the 28 days after each of the three vaccinations.",
            "startOffset": 37293,
            "title": "Safety and reactogenicity"
        },
        {
            "endOffset": 17057,
            "parents": [],
            "refoffsets": {
                "b0065": {
                    "endOffset": 17056,
                    "startOffset": 17052
                }
            },
            "secId": "s0005",
            "sentence": "Pfs25, one of the primary targets for TBV development, is a member of a protein family characterized by the presence of epidermal growth factor (EGF)-like repeat motifs, numerous cysteine residues and a complex tertiary structure [13].",
            "startOffset": 16822,
            "title": "Introduction"
        },
        {
            "endOffset": 22932,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Materials and methods"
                }
            ],
            "secId": "s0030",
            "sentence": "A total of 44 subjects were enrolled and sequentially assigned to one of four study vaccine groups to receive the Pfs25 VLP-FhCMB vaccine adjuvanted with Alhydrogel\u00ae, at the following vaccine doses: Group 1 (2 \u03bcg, 6 subjects), Group 2 (10 \u03bcg, 6 subjects), Group 3 (30 \u03bcg, 16 subjects) and Group 4 (100 \u03bcg, 16 subjects).",
            "startOffset": 22613,
            "title": "Vaccination schedule"
        },
        {
            "endOffset": 36982,
            "parents": [
                {
                    "id": "s0050",
                    "title": "Results"
                }
            ],
            "secId": "s0060",
            "sentence": "Unsolicited and solicited Treatment-Emergent AEs are summarized by severity in Table 2.",
            "startOffset": 36895,
            "title": "Safety and reactogenicity"
        },
        {
            "endOffset": 34795,
            "parents": [
                {
                    "id": "s0050",
                    "title": "Results"
                }
            ],
            "secId": "s0060",
            "sentence": "Overall, approximately 77% of subjects reported at least one AE, and approximately 23% of reported AEs were considered to be vaccination-related.",
            "startOffset": 34650,
            "title": "Safety and reactogenicity"
        },
        {
            "endOffset": 37126,
            "parents": [
                {
                    "id": "s0050",
                    "title": "Results"
                }
            ],
            "secId": "s0060",
            "sentence": "Overall, half of the subjects reported at least one Grade 1 Treatment-Emergent AE and half reported at least one Grade 2 Treatment-Emergent AE.",
            "startOffset": 36983,
            "title": "Safety and reactogenicity"
        },
        {
            "endOffset": 14970,
            "parents": [],
            "refoffsets": {
                "b0005": {
                    "endOffset": 14969,
                    "startOffset": 14966
                }
            },
            "secId": "s0005",
            "sentence": "Of the five species of malaria parasites that infect humans, Plasmodium falciparum is responsible for the majority of deaths [1].",
            "startOffset": 14841,
            "title": "Introduction"
        },
        {
            "endOffset": 30298,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Materials and methods"
                }
            ],
            "secId": "s0045",
            "sentence": "The percent of subjects with at least one event was compared between each vaccine treatment group using Fisher\u2019s exact test.",
            "startOffset": 30174,
            "title": "Statistical analysis"
        },
        {
            "endOffset": 38236,
            "parents": [
                {
                    "id": "s0050",
                    "title": "Results"
                }
            ],
            "secId": "s0060",
            "sentence": "Overall, approximately 55% of subjects reported at least one solicited systemic Treatment-Emergent AE, and 22 of these 24 subjects (approximately 90%) had Treatment-Emergent AEs of Grades 1 or 2 (Table 2).",
            "startOffset": 38031,
            "title": "Safety and reactogenicity"
        },
        {
            "endOffset": 38487,
            "parents": [
                {
                    "id": "s0050",
                    "title": "Results"
                }
            ],
            "secId": "s0060",
            "sentence": "The two subjects reporting a Grade 3 Treatment-Emergent AE were both in the 100 \u03bcg group (Table 2); one reported fatigue/malaise after the first vaccination and another reported diarrhea after the third vaccination (Supplementary material, Table S3).",
            "startOffset": 38237,
            "title": "Safety and reactogenicity"
        },
        {
            "endOffset": 43146,
            "parents": [],
            "secId": "s0070",
            "sentence": "Immune analysis of serum samples revealed that the vaccine elicited a good antibody response at total protein doses greater than 30 \u00b5g but a weak TRA response by SMFA.",
            "startOffset": 42979,
            "title": "Discussion"
        },
        {
            "endOffset": 32252,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Materials and methods"
                }
            ],
            "secId": "s0045",
            "sentence": "A binomial test was performed to determine whether the %TRA per group per study day was significantly different from no inhibition.",
            "startOffset": 32121,
            "title": "Statistical analysis"
        },
        {
            "endOffset": 20436,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Materials and methods"
                }
            ],
            "secId": "s0015",
            "sentence": "This study was registered at www.ClinicalTrials.gov under reference identifier NCT02013687.",
            "startOffset": 20345,
            "title": "Study design"
        },
        {
            "endOffset": 23777,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Materials and methods"
                }
            ],
            "secId": "s0030",
            "sentence": "On Study Day 0, two na\u00efve subjects of Group 1 received 2 \u03bcg of the Pfs25 VLP-FhCMB vaccine.",
            "startOffset": 23686,
            "title": "Vaccination schedule"
        },
        {
            "endOffset": 35005,
            "parents": [
                {
                    "id": "s0050",
                    "title": "Results"
                }
            ],
            "secId": "s0060",
            "sentence": "The highest (100 \u03bcg) dose group had the greatest percentage of subjects reporting at least one AE (approximately 94%) as well as subjects reporting vaccination-related AEs (N = 5, approximately 31%) (Table 2).",
            "startOffset": 34796,
            "title": "Safety and reactogenicity"
        },
        {
            "endOffset": 18510,
            "parents": [],
            "refoffsets": {
                "b0155": {
                    "endOffset": 18476,
                    "startOffset": 18472
                },
                "b0160": {
                    "endOffset": 18509,
                    "startOffset": 18505
                }
            },
            "secId": "s0005",
            "sentence": "Recently, a plant-based malaria vaccine candidate, Pfs25-CP VLP, which represents a chimeric non-enveloped VLP comprising Pfs25 fused to the Alfalfa mosaic virus coat protein (CP), has been engineered, transiently produced in Nicotiana benthamiana plants using a Tobacco mosaic virus (TMV)-based hybrid vector[31], purified and characterized [32].",
            "startOffset": 18163,
            "title": "Introduction"
        },
        {
            "endOffset": 23965,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Materials and methods"
                }
            ],
            "secId": "s0030",
            "sentence": "If there were no immediate safety issues, the remaining four subjects of this group received the 2 \u03bcg dose of the vaccine on Study Day 1 (approximately 24 h after the first two subjects).",
            "startOffset": 23778,
            "title": "Vaccination schedule"
        },
        {
            "endOffset": 33152,
            "parents": [
                {
                    "id": "s0050",
                    "title": "Results"
                }
            ],
            "secId": "s0055",
            "sentence": "The mean age of the participants was 34.3 years and the mean weight was 83.74 kg.",
            "startOffset": 33071,
            "title": "Study population"
        },
        {
            "endOffset": 23511,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Materials and methods"
                }
            ],
            "secId": "s0030",
            "sentence": "A total volume of 0.5 mL was injected per vaccination; vaccinations were administered in the deltoid muscle of the non-dominant arm.",
            "startOffset": 23379,
            "title": "Vaccination schedule"
        },
        {
            "endOffset": 35833,
            "parents": [
                {
                    "id": "s0050",
                    "title": "Results"
                }
            ],
            "secId": "s0060",
            "sentence": "None of the Treatment-Emergent AEs resulted in death or study discontinuation (Table 2).",
            "startOffset": 35745,
            "title": "Safety and reactogenicity"
        },
        {
            "endOffset": 44022,
            "parents": [],
            "secId": "s0070",
            "sentence": "Therefore, dosing based on Pfs25 content or reengineering of the particle to increase Pfs25 content could also enhance the TRA of the vaccine.",
            "startOffset": 43880,
            "title": "Discussion"
        },
        {
            "endOffset": 27828,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Materials and methods"
                }
            ],
            "secId": "s0040",
            "sentence": "Antibodies bound to the immobilized Pfs25 antigen were detected using horseradish peroxidase-conjugated goat anti-human IgG and o-Phenylenediamine dihydrochloride (SIGMAFAST OPD, Sigma-Aldrich).",
            "startOffset": 27634,
            "title": "Immunogenicity assessments"
        },
        {
            "endOffset": 31046,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Materials and methods"
                }
            ],
            "secId": "s0045",
            "sentence": "If a subject had multiple events occurring in the same body system or same preferred term, the event with the highest severity and the event with the strongest relatedness was counted for the summary of AEs by severity and by relatedness, respectively.",
            "startOffset": 30794,
            "title": "Statistical analysis"
        },
        {
            "endOffset": 44241,
            "parents": [],
            "secId": "s0070",
            "sentence": "There were no halts in dose escalation for this trial.",
            "startOffset": 44187,
            "title": "Discussion"
        },
        {
            "endOffset": 14577,
            "parents": [],
            "secId": "s0005",
            "sentence": "Malaria is a mosquito-borne, life-threatening, infectious disease caused by Plasmodium parasites.",
            "startOffset": 14480,
            "title": "Introduction"
        },
        {
            "endOffset": 21492,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Materials and methods"
                }
            ],
            "secId": "s0020",
            "sentence": "Four total protein dose levels of the vaccine (2, 10, 30 and 100 \u03bcg per 0.5 mL) were formulated in the clinic on the day of administration with 0.3% (w/w) aluminium hydroxide gel (Alhydrogel\u00ae) (to give 0.75 mg aluminium per 0.5 mL dose) adjuvant (Brenntag Biosector, Frederikssund, Denmark).",
            "startOffset": 21201,
            "title": "Vaccine"
        },
        {
            "endOffset": 25261,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Materials and methods"
                }
            ],
            "secId": "s0035",
            "sentence": "Visual assessments of the injection site were made prior to and 30 min post-injection on Study Days 0, 56 and 168, along with once each follow up visit.",
            "startOffset": 25109,
            "title": "Safety assessments"
        },
        {
            "endOffset": 34186,
            "parents": [
                {
                    "id": "s0050",
                    "title": "Results"
                }
            ],
            "secId": "s0060",
            "sentence": "Other than in the 100 \u03bcg group, there was no clinically meaningful pattern to the incidences of vaccine-related AEs.",
            "startOffset": 34070,
            "title": "Safety and reactogenicity"
        },
        {
            "endOffset": 27329,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Materials and methods"
                }
            ],
            "secId": "s0040",
            "sentence": "For immunogenicity assessments, sera were collected on Study Days 0 (pre-vaccination), 28 (1-month post primary vaccination), 56 (pre-vaccination), 84 (1-month post 2nd vaccination), 168 (pre-vaccination) and 196 (1-month post 3rd vaccination).",
            "startOffset": 27085,
            "title": "Immunogenicity assessments"
        },
        {
            "endOffset": 31672,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Materials and methods"
                }
            ],
            "secId": "s0045",
            "sentence": "Anti-Pfs25 IgG responses assessed by ELISA were analyzed by the non-parametric Friedman test to compare pre- (Study Day 0) versus post-vaccination (Study Days 28, 56, 84, 164 and 196) results.",
            "startOffset": 31480,
            "title": "Statistical analysis"
        },
        {
            "endOffset": 20345,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Materials and methods"
                }
            ],
            "secId": "s0015",
            "sentence": "Immunogenicity was assessed by measuring IgG antibody titers against Pfs25 by enzyme-linked immunosorbent assay (ELISA) and transmission reducing activity (TRA) by standard membrane feeding assay (SMFA).",
            "startOffset": 20142,
            "title": "Study design"
        },
        {
            "endOffset": 20795,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Materials and methods"
                }
            ],
            "secId": "s0020",
            "sentence": "The Pfs25 VLP-FhCMB vaccine, developed by Fraunhofer USA Center for Molecular Biotechnology (FhCMB), is a VLP containing the recombinant Pfs25 antigen from Plasmodium falciparum engineered to the Alfalfa mosaic virus CP and produced in hydroponically grown N. benthamiana plants using a recombinant A. tumefaciens-delivered, TMV-based hybrid vector.",
            "startOffset": 20446,
            "title": "Vaccine"
        },
        {
            "endOffset": 39028,
            "parents": [
                {
                    "id": "s0050",
                    "title": "Results"
                }
            ],
            "secId": "s0060",
            "sentence": "Overall, approximately 84% of subjects reported at least one solicited local TEAE, and 100% of that 84% had TEAEs considered Grades 1 or 2 (Table 2).",
            "startOffset": 38879,
            "title": "Safety and reactogenicity"
        },
        {
            "endOffset": 42257,
            "parents": [],
            "secId": "s0070",
            "sentence": "At the doses tested in this Phase 1 study, the vaccine was generally shown to be safe in healthy volunteers, with no incidence of vaccine-related Serious AEs and no evidence of any dose-limiting or dose-related toxicity.",
            "startOffset": 42037,
            "title": "Discussion"
        },
        {
            "endOffset": 32700,
            "parents": [
                {
                    "id": "s0050",
                    "title": "Results"
                }
            ],
            "secId": "s0055",
            "sentence": "In the 30 \u03bcg group, one subject was \u201cLost to Follow-up\u201d and another was discontinued because of inability to adhere to the visits schedule; both subjects received all three planned vaccinations.",
            "startOffset": 32506,
            "title": "Study population"
        },
        {
            "endOffset": 36446,
            "parents": [
                {
                    "id": "s0050",
                    "title": "Results"
                }
            ],
            "secId": "s0060",
            "sentence": "Overall, half of the subjects reported at least one Grade 1 Treatment-Emergent AE and half reported at least one Grade 2 Treatment-Emergent AE.",
            "startOffset": 36303,
            "title": "Safety and reactogenicity"
        },
        {
            "endOffset": 40974,
            "parents": [
                {
                    "id": "s0050",
                    "title": "Results"
                }
            ],
            "secId": "s0065",
            "sentence": "Both 30 and 100 \u03bcg dose groups did not show significant TRA activity after the 2nd vaccination (p = 0.598 and 0.304 by binomial tests, respectively), when purified IgG was tested at 3.75 mg/mL.",
            "startOffset": 40781,
            "title": "Immunogenicity"
        },
        {
            "endOffset": 33692,
            "parents": [
                {
                    "id": "s0050",
                    "title": "Results"
                }
            ],
            "secId": "s0060",
            "sentence": "The highest (100 \u03bcg) dose group had the greatest percentage of subjects reporting at least one AE (approximately 94%) as well as subjects reporting vaccination-related AEs (N = 5, approximately 31%) (Table 2).",
            "startOffset": 33483,
            "title": "Safety and reactogenicity"
        },
        {
            "endOffset": 17759,
            "parents": [],
            "refoffsets": {
                "b0075": {
                    "endOffset": 17583,
                    "startOffset": 17576
                },
                "b0080": {
                    "endOffset": 17583,
                    "startOffset": 17576
                },
                "b0085": {
                    "endOffset": 17583,
                    "startOffset": 17576
                },
                "b0090": {
                    "endOffset": 17583,
                    "startOffset": 17576
                },
                "b0095": {
                    "endOffset": 17583,
                    "startOffset": 17576
                },
                "b0100": {
                    "endOffset": 17583,
                    "startOffset": 17576
                },
                "b0105": {
                    "endOffset": 17583,
                    "startOffset": 17576
                },
                "b0110": {
                    "endOffset": 17583,
                    "startOffset": 17576
                },
                "b0115": {
                    "endOffset": 17583,
                    "startOffset": 17576
                },
                "b0120": {
                    "endOffset": 17758,
                    "startOffset": 17751
                },
                "b0125": {
                    "endOffset": 17758,
                    "startOffset": 17751
                }
            },
            "secId": "s0005",
            "sentence": "Despite these challenges, recent success has been achieved with recombinant versions of Pfs25 proteins produced in yeast that are emerging as prominent TBV candidates [15\u201323]; the leading candidate being a Pichia pastoris produced Pfs25 (PpPfs25H-A) chemically conjugated to the mutant, non-toxic ExoProtein A (EPA) of Pseudomonas aeruginosa [24,25].",
            "startOffset": 17409,
            "title": "Introduction"
        },
        {
            "endOffset": 42979,
            "parents": [],
            "secId": "s0070",
            "sentence": "Evaluation of laboratory assessments and vital signs were unremarkable and resulted in no adverse events reported.",
            "startOffset": 42865,
            "title": "Discussion"
        },
        {
            "endOffset": 32421,
            "parents": [
                {
                    "id": "s0050",
                    "title": "Results"
                }
            ],
            "secId": "s0055",
            "sentence": "Of 44 subjects that were enrolled, all received the 1st scheduled vaccination and all were included in the safety and immunogenicity analyses.",
            "startOffset": 32279,
            "title": "Study population"
        },
        {
            "endOffset": 19678,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Materials and methods"
                }
            ],
            "secId": "s0015",
            "sentence": "The study was conducted in accordance with the principles of the Declaration of Helsinki, the standards of Good Clinical Practice (as defined by the International Conference on Harmonization) and federal regulations.",
            "startOffset": 19462,
            "title": "Study design"
        },
        {
            "endOffset": 16663,
            "parents": [],
            "secId": "s0005",
            "sentence": "Identified targets of effective TB immunity are proteins expressed on the surface of gametocytes/gametes, zygotes and ookinetes, as well as mosquito encoded proteins in the mid-gut.",
            "startOffset": 16482,
            "title": "Introduction"
        },
        {
            "endOffset": 16822,
            "parents": [],
            "refoffsets": {
                "b0055": {
                    "endOffset": 16821,
                    "startOffset": 16814
                },
                "b0060": {
                    "endOffset": 16821,
                    "startOffset": 16814
                }
            },
            "secId": "s0005",
            "sentence": "For example, antibodies against the Plasmodium proteins Pfs25, Pfs28, Pfs48/45 or Pfs230 have been shown to block parasite transmission to mosquitoes [11,12].",
            "startOffset": 16664,
            "title": "Introduction"
        },
        {
            "endOffset": 18162,
            "parents": [],
            "refoffsets": {
                "b0150": {
                    "endOffset": 18161,
                    "startOffset": 18157
                }
            },
            "secId": "s0005",
            "sentence": "Virus-like particles (VLPs) are a class of subunit vaccines that induce the strongest protective immunity [30].",
            "startOffset": 18051,
            "title": "Introduction"
        },
        {
            "endOffset": 15627,
            "parents": [],
            "secId": "s0005",
            "sentence": "Presently, there is only one licensed malaria vaccine available for areas where Plasmodium falciparum is prevalent.",
            "startOffset": 15512,
            "title": "Introduction"
        },
        {
            "endOffset": 33016,
            "parents": [
                {
                    "id": "s0050",
                    "title": "Results"
                }
            ],
            "secId": "s0055",
            "sentence": "The subject baseline demographic characteristics are summarized in Table 1.",
            "startOffset": 32941,
            "title": "Study population"
        },
        {
            "endOffset": 43415,
            "parents": [],
            "secId": "s0070",
            "sentence": "Therefore, the incorporation of a stronger, more potent adjuvant that has a history of safety in humans could enhance the efficacy of the Pfs25 VLP-FhCMB vaccine.",
            "startOffset": 43253,
            "title": "Discussion"
        },
        {
            "endOffset": 29320,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Materials and methods"
                }
            ],
            "secId": "s0040",
            "sentence": "The SMFA was performed at the Laboratory of Malaria and Vector Research, NIAID, NIH, Rockville, MD.",
            "startOffset": 29221,
            "title": "Immunogenicity assessments"
        },
        {
            "endOffset": 23686,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Materials and methods"
                }
            ],
            "secId": "s0030",
            "sentence": "The safety and tolerability of each vaccine dose level were assessed before moving to the next dose level, using pre-specified halting/holding rules (defined in Section 2.5).",
            "startOffset": 23512,
            "title": "Vaccination schedule"
        },
        {
            "endOffset": 26406,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Materials and methods"
                }
            ],
            "secId": "s0035",
            "sentence": "All solicited local AEs were considered vaccine-related.",
            "startOffset": 26350,
            "title": "Safety assessments"
        },
        {
            "endOffset": 35382,
            "parents": [
                {
                    "id": "s0050",
                    "title": "Results"
                }
            ],
            "secId": "s0060",
            "sentence": "The subject who reported possibly related injection site pruritus also reported definitely related injection site pruritus that occurred outside the 28-day post vaccination period.",
            "startOffset": 35202,
            "title": "Safety and reactogenicity"
        },
        {
            "endOffset": 17408,
            "parents": [],
            "refoffsets": {
                "b0070": {
                    "endOffset": 17407,
                    "startOffset": 17403
                }
            },
            "secId": "s0005",
            "sentence": "Additionally, Plasmodium parasites lack the N-linked glycosylation machinery, and many Plasmodium proteins contain multiple potential glycosylation sites that are aberrantly glycosylated when expressed in any of the available eukaryotic hosts [14].",
            "startOffset": 17160,
            "title": "Introduction"
        },
        {
            "endOffset": 19461,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Materials and methods"
                }
            ],
            "secId": "s0015",
            "sentence": "The study protocol (FhCMB Pfs25-001) and the informed consent form were approved by the Western Institutional Review Board (WIRB, Olympia, WA; Protocol Number: 20131400).",
            "startOffset": 19291,
            "title": "Study design"
        },
        {
            "endOffset": 28956,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Materials and methods"
                }
            ],
            "secId": "s0040",
            "sentence": "In the presence of functional antibody, the development of oocysts is inhibited, thus the reduction in the number of oocysts compared to the control is a measure of a sample\u2019s TRA.",
            "startOffset": 28776,
            "title": "Immunogenicity assessments"
        },
        {
            "endOffset": 34566,
            "parents": [
                {
                    "id": "s0050",
                    "title": "Results"
                }
            ],
            "secId": "s0060",
            "sentence": "Supplementary data associated with this article can be found, in the online version, at https://doi.org/10.1016/j.vaccine.2018.08.033.",
            "startOffset": 34432,
            "title": "Safety and reactogenicity"
        },
        {
            "endOffset": 27435,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Materials and methods"
                }
            ],
            "secId": "s0040",
            "sentence": "To assess the anti-Pfs25 IgG responses at these time points, an ELISA was conducted on the serum samples.",
            "startOffset": 27330,
            "title": "Immunogenicity assessments"
        },
        {
            "endOffset": 41448,
            "parents": [
                {
                    "id": "s0050",
                    "title": "Results"
                }
            ],
            "secId": "s0065",
            "sentence": "Selected Day 196 samples (5 from the 30 \u00b5g and 8 from the 100 \u03bcg dose group) were further tested at higher concentration, 15 mg/mL, in SMFA.",
            "startOffset": 41308,
            "title": "Immunogenicity"
        },
        {
            "endOffset": 31918,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Materials and methods"
                }
            ],
            "secId": "s0045",
            "sentence": "The TRA of the test serum samples measured by SMFA was expressed as mean percent inhibition of mean oocyst density (%TRA).",
            "startOffset": 31796,
            "title": "Statistical analysis"
        },
        {
            "endOffset": 15511,
            "parents": [],
            "secId": "s0005",
            "sentence": "Thus, effective vaccines for the control and prevention of malaria are urgently needed, as vaccination remains one of the most efficient and cost-effective methods for controlling infectious diseases.",
            "startOffset": 15311,
            "title": "Introduction"
        },
        {
            "endOffset": 38031,
            "parents": [
                {
                    "id": "s0050",
                    "title": "Results"
                }
            ],
            "secId": "s0060",
            "sentence": "The two subjects reporting a Grade 3 Treatment-Emergent AE were both in the 100 \u03bcg group (Table 2); one reported fatigue/malaise after the first vaccination and another reported diarrhea after the third vaccination (Supplementary material, Table S3).",
            "startOffset": 37781,
            "title": "Safety and reactogenicity"
        },
        {
            "endOffset": 15310,
            "parents": [],
            "refoffsets": {
                "b0010": {
                    "endOffset": 15309,
                    "startOffset": 15306
                }
            },
            "secId": "s0005",
            "sentence": "However, recurring drug resistance compromises the efficiency of both old and new antimalarial medicines [2].",
            "startOffset": 15201,
            "title": "Introduction"
        },
        {
            "endOffset": 42864,
            "parents": [],
            "secId": "s0070",
            "sentence": "The most frequent solicited systemic AEs across the dose groups were fatigue/malaise, headache and myalgia; the only injection site reactions were pain and tenderness AEs, most of which were considered mild.",
            "startOffset": 42657,
            "title": "Discussion"
        },
        {
            "endOffset": 35745,
            "parents": [
                {
                    "id": "s0050",
                    "title": "Results"
                }
            ],
            "secId": "s0060",
            "sentence": "Across the three 28-day post-vaccination periods, the overall total proportion of subjects reporting at least one AE, as well as the percentage of subjects reporting vaccination-related AEs, tended to decrease (Supplementary material, Table S1).",
            "startOffset": 35500,
            "title": "Safety and reactogenicity"
        },
        {
            "endOffset": 29586,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Materials and methods"
                }
            ],
            "secId": "s0040",
            "sentence": "The immunologic criterion for study continuation and the Go or No-Go decision were based on TRA showing \u226580% reduction in oocysts in \u226550% sera obtained 28 days post 3rd vaccination (Study Day 196) in either Group 3 or 4 subjects compared to the pre-vaccination sera.",
            "startOffset": 29320,
            "title": "Immunogenicity assessments"
        },
        {
            "endOffset": 35201,
            "parents": [
                {
                    "id": "s0050",
                    "title": "Results"
                }
            ],
            "secId": "s0060",
            "sentence": "Of these 5 subjects, 1 reported injection site pruritus (not reported as a solicited AE; possibly related) and 2 subjects reported muscle spasm (possibly related) within 28 days post vaccination.",
            "startOffset": 35006,
            "title": "Safety and reactogenicity"
        },
        {
            "endOffset": 19779,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Materials and methods"
                }
            ],
            "secId": "s0015",
            "sentence": "All participants provided written informed consent prior to screening and enrollment into the study.",
            "startOffset": 19679,
            "title": "Study design"
        },
        {
            "endOffset": 41167,
            "parents": [
                {
                    "id": "s0050",
                    "title": "Results"
                }
            ],
            "secId": "s0065",
            "sentence": "While the 30 \u03bcg dose group showed insignificant inhibition post 3rd dose (p = 0.607), the 100 \u00b5g dose group showed a weak (36.2% on median), but significant, inhibition as a group (p = 0.002).",
            "startOffset": 40975,
            "title": "Immunogenicity"
        },
        {
            "endOffset": 19085,
            "parents": [],
            "secId": "s0005",
            "sentence": "Subsequently, this malaria vaccine candidate, named Pfs25 VLP-FhCMB, was produced in N. benthamiana at pilot plant scale under current Good Manufacturing Practice (cGMP) guidelines, and results on safety, reactogenicity and immunogenicity assessed in healthy adult volunteers are presented here.",
            "startOffset": 18790,
            "title": "Introduction"
        },
        {
            "endOffset": 28304,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Materials and methods"
                }
            ],
            "secId": "s0040",
            "sentence": "Titers below the limit of quantification (LOQ) were assigned a value of 10.",
            "startOffset": 28229,
            "title": "Immunogenicity assessments"
        },
        {
            "endOffset": 28775,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Materials and methods"
                }
            ],
            "secId": "s0040",
            "sentence": "Pre-immune controls were run in every assay and the reduction in the number of oocysts for each test sample was calculated as a comparison to the corresponding pre-immune control samples.",
            "startOffset": 28588,
            "title": "Immunogenicity assessments"
        },
        {
            "endOffset": 30793,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Materials and methods"
                }
            ],
            "secId": "s0045",
            "sentence": "All AEs were coded and summarized by system organ class and preferred term using the Medical Dictionary for Drug Regulatory Activities (MedDRA) Dictionary (version 16.0).",
            "startOffset": 30623,
            "title": "Statistical analysis"
        },
        {
            "endOffset": 28228,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Materials and methods"
                }
            ],
            "secId": "s0040",
            "sentence": "The endpoint titer of each test sample was calculated as the reciprocal dilution at an optical density (OD) of 1 determined by a 4-parameter curve fit using SoftMax Pro v.5.3 (Molecular Devices).",
            "startOffset": 28033,
            "title": "Immunogenicity assessments"
        },
        {
            "endOffset": 24236,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Materials and methods"
                }
            ],
            "secId": "s0030",
            "sentence": "Safety data was collected for 6 days following each group vaccination and was reviewed by the Principal Investigator and the Safety Monitoring Committee (SMC) to ensure that neither Stop nor Hold criteria had been met prior to the administration of the next higher dose.",
            "startOffset": 23966,
            "title": "Vaccination schedule"
        },
        {
            "endOffset": 26173,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Materials and methods"
                }
            ],
            "secId": "s0035",
            "sentence": "Unsolicited Treatment-Emergent AEs were assessed for severity and graded as 1 = mild, not interfering with routine activities, minimal level of discomfort; 2 = moderate, interfering with routine activities, moderate level of discomfort; or 3 = severe, unable to perform routine activities, significant level of discomfort.",
            "startOffset": 25851,
            "title": "Safety assessments"
        },
        {
            "endOffset": 43252,
            "parents": [],
            "secId": "s0070",
            "sentence": "A contributing factor to the weak TRA could be the use of Alhydrogel adjuvant in the vaccine formulation.",
            "startOffset": 43147,
            "title": "Discussion"
        },
        {
            "endOffset": 30024,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Materials and methods"
                }
            ],
            "secId": "s0045",
            "sentence": "For extent of exposure, the number and percent of subjects were tabulated by the number of doses received.",
            "startOffset": 29918,
            "title": "Statistical analysis"
        },
        {
            "endOffset": 17159,
            "parents": [],
            "secId": "s0005",
            "sentence": "Therefore, it has been difficult to produce Pfs25 with accurate conformation in heterologous systems.",
            "startOffset": 17058,
            "title": "Introduction"
        },
        {
            "endOffset": 28032,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Materials and methods"
                }
            ],
            "secId": "s0040",
            "sentence": "After enzyme-substrate reaction was stopped by addition of 5 M sulfuric acid solution, the plates were read at 490 nm with 650 nm as a reference using Spectramax M2 microplate reader (Molecular Devices).",
            "startOffset": 27829,
            "title": "Immunogenicity assessments"
        },
        {
            "endOffset": 40602,
            "parents": [
                {
                    "id": "s0050",
                    "title": "Results"
                }
            ],
            "secId": "s0065",
            "sentence": "TRA assessment showed that none of the dose groups demonstrated a pre-determined target of \u226580% reduction in oocysts 1 month after the 2nd (Day 84) or 3rd (Day 196) vaccination (Fig. 2).",
            "startOffset": 40416,
            "title": "Immunogenicity"
        },
        {
            "endOffset": 32505,
            "parents": [
                {
                    "id": "s0050",
                    "title": "Results"
                }
            ],
            "secId": "s0055",
            "sentence": "Two subjects in each of the 30 \u03bcg and 100 \u03bcg groups discontinued the study earlier.",
            "startOffset": 32422,
            "title": "Study population"
        },
        {
            "endOffset": 27633,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Materials and methods"
                }
            ],
            "secId": "s0040",
            "sentence": "Serially diluted test serum samples, starting at a 1:100 dilution, were added to the plates.",
            "startOffset": 27541,
            "title": "Immunogenicity assessments"
        },
        {
            "endOffset": 29757,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Materials and methods"
                }
            ],
            "secId": "s0045",
            "sentence": "Statistical analyses were performed by MacroStat Inc. on a final adjudicated locked database using Statistical Analysis Software (SAS)\u00ae version 9.3.",
            "startOffset": 29609,
            "title": "Statistical analysis"
        },
        {
            "endOffset": 43879,
            "parents": [],
            "refoffsets": {
                "b0160": {
                    "endOffset": 43878,
                    "startOffset": 43874
                }
            },
            "secId": "s0070",
            "sentence": "This is less than would be predicted from prior preparations at smaller scale, where 20\u201330% of CP molecules carried Pfs25 [32].",
            "startOffset": 43752,
            "title": "Discussion"
        },
        {
            "endOffset": 36612,
            "parents": [
                {
                    "id": "s0050",
                    "title": "Results"
                }
            ],
            "secId": "s0060",
            "sentence": "In general, subjects in the 2 and 10 \u03bcg dose groups reported Grade 2 Treatment-Emergent AEs, while subjects in the 30 and 100 \u03bcg dose groups reported Grade 1 events.",
            "startOffset": 36447,
            "title": "Safety and reactogenicity"
        },
        {
            "endOffset": 39405,
            "parents": [
                {
                    "id": "s0050",
                    "title": "Results"
                }
            ],
            "secId": "s0060",
            "sentence": "Most of these injection site reactions were considered mild discomfort to touch or did not interfere with activity.",
            "startOffset": 39290,
            "title": "Safety and reactogenicity"
        },
        {
            "endOffset": 40780,
            "parents": [
                {
                    "id": "s0050",
                    "title": "Results"
                }
            ],
            "secId": "s0065",
            "sentence": "Due to the undetectable or low anti-Pfs25 antibody titers 1-month post 2nd and 3rd vaccination in the 2 \u03bcg and 10 \u03bcg dose groups, TRA activity was not evaluated in these groups.",
            "startOffset": 40603,
            "title": "Immunogenicity"
        },
        {
            "endOffset": 39609,
            "parents": [
                {
                    "id": "s0050",
                    "title": "Results"
                }
            ],
            "secId": "s0060",
            "sentence": "None of the changes occurring in hematology or clinical chemistry parameters during the study were considered clinically meaningful, demonstrating no safety concerns with any dose group (data not shown).",
            "startOffset": 39406,
            "title": "Safety and reactogenicity"
        },
        {
            "endOffset": 32940,
            "parents": [
                {
                    "id": "s0050",
                    "title": "Results"
                }
            ],
            "secId": "s0055",
            "sentence": "In the 100 \u03bcg group, one subject withdrew consent and received only two vaccine doses, and another was discontinued because of \u201cKnown illicit and/or intravenous drug abuse\u201d (an exclusion criterion) and only received the first vaccine dose.",
            "startOffset": 32701,
            "title": "Study population"
        },
        {
            "endOffset": 22130,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Materials and methods"
                }
            ],
            "secId": "s0025",
            "sentence": "Major exclusion criteria included women who were pregnant, lactating, or planning on becoming pregnant during the study period and subjects with a history of malaria or previous receipt of an investigational malaria vaccine, being seropositive for hepatitis B surface antigen (HBsAg), hepatitis C antibodies (anti-HCV) or human immunodeficiency.",
            "startOffset": 21785,
            "title": "Inclusion and exclusion criteria"
        },
        {
            "endOffset": 26349,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Materials and methods"
                }
            ],
            "secId": "s0035",
            "sentence": "Vaccine-related AEs (possibly related or definitely related) were those that the investigator judged as having a reasonable possibility that the vaccine contributed to the AE.",
            "startOffset": 26174,
            "title": "Safety assessments"
        },
        {
            "endOffset": 29150,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Materials and methods"
                }
            ],
            "secId": "s0040",
            "sentence": "Each IgG sample was tested at 3.75 mg/mL in two independent assays, and if the two data sets did not match (i.e., 95% confidence intervals of % TRA did not overlap) a third assay was conducted.",
            "startOffset": 28957,
            "title": "Immunogenicity assessments"
        },
        {
            "endOffset": 38879,
            "parents": [
                {
                    "id": "s0050",
                    "title": "Results"
                }
            ],
            "secId": "s0060",
            "sentence": "The highest incidences of solicited systemic AEs after any vaccination were fatigue/malaise (\u223c33%), myalgia (\u223c33%) and chills (\u223c33%) in the 2 \u03bcg dose group; fatigue/malaise (\u223c33%) and headache (50%) in the 10 \u03bcg dose group; fatigue/malaise (25%) and headache (\u223c31%) in the 30 \u03bcg dose group; and headache (25%), nausea (25%), myalgia (\u223c31%) and fatigue/malaise (\u223c38%) in the 100 \u03bcg dose group.",
            "startOffset": 38487,
            "title": "Safety and reactogenicity"
        },
        {
            "endOffset": 25453,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Materials and methods"
                }
            ],
            "secId": "s0035",
            "sentence": "Solicited general Treatment-Emergent AEs were fever, myalgia, chills, sweats, fatigue/malaise, arthralgia, headache, nausea, vomiting or diarrhea; their severity was graded as Grade 1, 2 or 3.",
            "startOffset": 25261,
            "title": "Safety assessments"
        },
        {
            "endOffset": 42656,
            "parents": [],
            "secId": "s0070",
            "sentence": "Further, across the three 28-day post-vaccination periods the overall total proportion of subjects reporting at least one AE tended to decrease as did the percentage of subjects reporting vaccination-related AEs.",
            "startOffset": 42444,
            "title": "Discussion"
        },
        {
            "endOffset": 40416,
            "parents": [
                {
                    "id": "s0050",
                    "title": "Results"
                }
            ],
            "secId": "s0065",
            "sentence": "In the 100 \u00b5g dose group, statistically significant increases in anti-Pfs25 IgG titers, as compared to pre-vaccination levels, were observed on Study Days 84 and 196, 1 month after each vaccination (p < 0.0001, Fig. 1).",
            "startOffset": 40197,
            "title": "Immunogenicity"
        },
        {
            "endOffset": 31480,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Materials and methods"
                }
            ],
            "secId": "s0045",
            "sentence": "Mean changes among vaccine treatment groups were analyzed using an analysis of covariance (ANCOVA) model with an effect for vaccine treatment and baseline value as a covariate for each visit.",
            "startOffset": 31289,
            "title": "Statistical analysis"
        },
        {
            "endOffset": 44499,
            "parents": [],
            "secId": "s0070",
            "sentence": "Although the trial did not meet the TRA criterion in the two higher dose groups, the 100 \u00b5g dose did demonstrate a weak, but significant, TRA after the 3rd vaccination, suggesting the potential of this vaccine to induce functional antibody titers in humans.",
            "startOffset": 44242,
            "title": "Discussion"
        },
        {
            "endOffset": 31124,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Materials and methods"
                }
            ],
            "secId": "s0045",
            "sentence": "No statistical inference between the vaccine treatments was performed on AEs.",
            "startOffset": 31047,
            "title": "Statistical analysis"
        },
        {
            "endOffset": 44186,
            "parents": [],
            "secId": "s0070",
            "sentence": "In conclusion, the study was successful in demonstrating an acceptable safety, reactogenicity and tolerability profile of the plant-derived Pfs25 VLP-FhCMB vaccine.",
            "startOffset": 44022,
            "title": "Discussion"
        },
        {
            "endOffset": 37780,
            "parents": [
                {
                    "id": "s0050",
                    "title": "Results"
                }
            ],
            "secId": "s0060",
            "sentence": "Overall, approximately 55% of subjects reported at least one solicited systemic Treatment-Emergent AE, and 22 of these 24 subjects (approximately 90%) had Treatment-Emergent AEs of Grades 1 or 2 (Table 2).",
            "startOffset": 37575,
            "title": "Safety and reactogenicity"
        },
        {
            "endOffset": 21784,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Materials and methods"
                }
            ],
            "secId": "s0025",
            "sentence": "Subjects were healthy, as determined by medical history, physical examination, vital signs, and clinical safety laboratory examination at baseline, male or female adults aged 18\u201350 years (inclusive) at first vaccination, who had met the enrollment criteria.",
            "startOffset": 21527,
            "title": "Inclusion and exclusion criteria"
        },
        {
            "endOffset": 24406,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Materials and methods"
                }
            ],
            "secId": "s0030",
            "sentence": "There was an approximate 14-day stagger between each group dose escalation with the same safety follow-up procedures and SMC review occurring after each dose escalation.",
            "startOffset": 24237,
            "title": "Vaccination schedule"
        },
        {
            "endOffset": 16481,
            "parents": [],
            "secId": "s0005",
            "sentence": "TBVs aim to prevent sexual stage parasites ingested by female Anopheles mosquitoes from undergoing successful sporogonic development, thus preventing transmission from mosquito to a potential human host and subsequent spread of parasites in endemic populations.",
            "startOffset": 16220,
            "title": "Introduction"
        },
        {
            "endOffset": 15200,
            "parents": [],
            "secId": "s0005",
            "sentence": "Furthermore, antimalarial medicines can be used both prophylactically and for curative treatment.",
            "startOffset": 15103,
            "title": "Introduction"
        },
        {
            "endOffset": 42443,
            "parents": [],
            "secId": "s0070",
            "sentence": "As expected, the 100 \u03bcg dose group had the greatest percentage of subjects reporting vaccination-related AEs (approximately 31%).",
            "startOffset": 42314,
            "title": "Discussion"
        },
        {
            "endOffset": 33888,
            "parents": [
                {
                    "id": "s0050",
                    "title": "Results"
                }
            ],
            "secId": "s0060",
            "sentence": "Of these 5 subjects, 1 reported injection site pruritus (not reported as a solicited AE; possibly related) and 2 subjects reported muscle spasm (possibly related) within 28 days post vaccination.",
            "startOffset": 33693,
            "title": "Safety and reactogenicity"
        },
        {
            "endOffset": 20004,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Materials and methods"
                }
            ],
            "secId": "s0015",
            "sentence": "The primary objective of this study was to assess the safety, reactogenicity and tolerability of the Pfs25 VLP-FhCMB vaccine delivered IM at doses of 2, 10, 30 and 100 \u03bcg of total protein in healthy adults 18\u201350 years of age.",
            "startOffset": 19779,
            "title": "Study design"
        },
        {
            "endOffset": 29220,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Materials and methods"
                }
            ],
            "secId": "s0040",
            "sentence": "For selected samples, IgGs were tested at 15 mg/mL in a single assay.",
            "startOffset": 29151,
            "title": "Immunogenicity assessments"
        },
        {
            "endOffset": 36707,
            "parents": [
                {
                    "id": "s0050",
                    "title": "Results"
                }
            ],
            "secId": "s0060",
            "sentence": "This pattern was generally consistent during the 28 days after each of the three vaccinations.",
            "startOffset": 36613,
            "title": "Safety and reactogenicity"
        },
        {
            "endOffset": 20141,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Materials and methods"
                }
            ],
            "secId": "s0015",
            "sentence": "The secondary objective was to assess the immunogenicity of the candidate vaccine administered with Alhydrogel after three vaccinations.",
            "startOffset": 20005,
            "title": "Study design"
        },
        {
            "endOffset": 41596,
            "parents": [
                {
                    "id": "s0050",
                    "title": "Results"
                }
            ],
            "secId": "s0065",
            "sentence": "In these assays, 2 out of the 8 patient samples tested from the 100 \u00b5g dose group, had significant %TRA values near 80%: 81% and 77%, respectively.",
            "startOffset": 41449,
            "title": "Immunogenicity"
        },
        {
            "endOffset": 43751,
            "parents": [],
            "secId": "s0070",
            "sentence": "The doses used in this study were based on total protein values, of which the majority is the CP from the alfalfa mosaic virus leaving the actual Pfs25 content around 1/10 of the total dose amount.",
            "startOffset": 43554,
            "title": "Discussion"
        },
        {
            "endOffset": 33225,
            "parents": [
                {
                    "id": "s0050",
                    "title": "Results"
                }
            ],
            "secId": "s0055",
            "sentence": "The majority of the participants (63.6%) were Black or African American.",
            "startOffset": 33153,
            "title": "Study population"
        },
        {
            "endOffset": 16219,
            "parents": [],
            "secId": "s0005",
            "sentence": "These initiatives to eliminate/eradicate malaria have intensified the interest in developing transmission blocking (TB) vaccines (TBVs).",
            "startOffset": 16083,
            "title": "Introduction"
        },
        {
            "endOffset": 41307,
            "parents": [
                {
                    "id": "s0050",
                    "title": "Results"
                }
            ],
            "secId": "s0065",
            "sentence": "However, no subject generated greater than or equal to 80% TRA throughout the study period when tested at IgG concentrations of 3.75 mg/mL.",
            "startOffset": 41168,
            "title": "Immunogenicity"
        },
        {
            "endOffset": 24828,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Materials and methods"
                }
            ],
            "secId": "s0030",
            "sentence": "The final scheduled blood draw (evaluating safety and immunogenicity) occurred on Study Day 252 with a telephone follow-up for safety on Study Day 336.",
            "startOffset": 24677,
            "title": "Vaccination schedule"
        },
        {
            "endOffset": 33482,
            "parents": [
                {
                    "id": "s0050",
                    "title": "Results"
                }
            ],
            "secId": "s0060",
            "sentence": "Overall, approximately 77% of subjects reported at least one AE, and approximately 23% of reported AEs were considered to be vaccination-related.",
            "startOffset": 33337,
            "title": "Safety and reactogenicity"
        },
        {
            "endOffset": 33070,
            "parents": [
                {
                    "id": "s0050",
                    "title": "Results"
                }
            ],
            "secId": "s0055",
            "sentence": "Overall, approximately 60% of participants were male.",
            "startOffset": 33017,
            "title": "Study population"
        },
        {
            "endOffset": 20920,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Materials and methods"
                }
            ],
            "refoffsets": {
                "b0160": {
                    "endOffset": 20919,
                    "startOffset": 20915
                }
            },
            "secId": "s0020",
            "sentence": "The Pfs25-CP fusion antigen was cloned, expressed in N. benthamiana, purified and characterized as reported previously [32].",
            "startOffset": 20796,
            "title": "Vaccine"
        },
        {
            "endOffset": 19290,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Materials and methods"
                }
            ],
            "secId": "s0015",
            "sentence": "This was a Phase 1, single-center, open-label, non-randomized, dose-escalation clinical study conducted at the Optimal Research, Accelovance Inc. (Rockville, Maryland).",
            "startOffset": 19122,
            "title": "Study design"
        },
        {
            "endOffset": 14840,
            "parents": [],
            "secId": "s0005",
            "sentence": "According to the World Malaria Report 2016, about 212 million cases of malaria were reported worldwide in 2015, predominantly in sub-Saharan Africa and South-East Asia, causing approximately 303,000 deaths, mostly among African children under the age of 5 years.",
            "startOffset": 14578,
            "title": "Introduction"
        },
        {
            "endOffset": 39900,
            "parents": [
                {
                    "id": "s0050",
                    "title": "Results"
                }
            ],
            "secId": "s0065",
            "sentence": "There was no significant increase in anti-Pfs25 IgG titers as measured by ELISA after vaccination in the 2 or 10 \u00b5g dose groups when compared to the pre-vaccination level (data not shown), except for 1 month after the 3rd vaccination (Study Day 196) in the 10 \u00b5g dose group.",
            "startOffset": 39626,
            "title": "Immunogenicity"
        },
        {
            "endOffset": 35499,
            "parents": [
                {
                    "id": "s0050",
                    "title": "Results"
                }
            ],
            "secId": "s0060",
            "sentence": "Other than in the 100 \u03bcg group, there was no clinically meaningful pattern to the incidences of vaccine-related AEs.",
            "startOffset": 35383,
            "title": "Safety and reactogenicity"
        },
        {
            "endOffset": 30623,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Materials and methods"
                }
            ],
            "secId": "s0045",
            "sentence": "If a subject had multiple events occurring in the same event term, the event with the highest severity was counted.",
            "startOffset": 30508,
            "title": "Statistical analysis"
        },
        {
            "endOffset": 23284,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Materials and methods"
                }
            ],
            "secId": "s0030",
            "sentence": "The vaccination schedule was started with the lowest dose group and progressed group by group to higher dose groups.",
            "startOffset": 23168,
            "title": "Vaccination schedule"
        },
        {
            "endOffset": 43553,
            "parents": [],
            "secId": "s0070",
            "sentence": "In addition, the lack of robust functional immune responses may be due to a suboptimal dose of the target antigen, Pfs25, in the vaccine.",
            "startOffset": 43416,
            "title": "Discussion"
        },
        {
            "endOffset": 37292,
            "parents": [
                {
                    "id": "s0050",
                    "title": "Results"
                }
            ],
            "secId": "s0060",
            "sentence": "In general, subjects in the 2 and 10 \u03bcg dose groups reported Grade 2 Treatment-Emergent AEs, while subjects in the 30 and 100 \u03bcg dose groups reported Grade 1 events.",
            "startOffset": 37127,
            "title": "Safety and reactogenicity"
        },
        {
            "endOffset": 39289,
            "parents": [
                {
                    "id": "s0050",
                    "title": "Results"
                }
            ],
            "secId": "s0060",
            "sentence": "Pain and tenderness were the only injection site reactions reported among all subjects, and tenderness was the one most frequently reported.",
            "startOffset": 39149,
            "title": "Safety and reactogenicity"
        },
        {
            "endOffset": 36895,
            "parents": [
                {
                    "id": "s0050",
                    "title": "Results"
                }
            ],
            "secId": "s0060",
            "sentence": "Within the 28 days after each of the three vaccinations, no more than one subject reported a specific Treatment-Emergent AE that was considered Grade 2 (Supplementary material, Table S2).",
            "startOffset": 36708,
            "title": "Safety and reactogenicity"
        },
        {
            "endOffset": 25850,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Materials and methods"
                }
            ],
            "secId": "s0035",
            "sentence": "Additional grading scales were applied to visible swelling or redness at the injection site (1 = 2.5\u20135 cm, 2 = 5.1\u201310 cm and 3 = >10 cm) and to fever (1 = 38.0\u201338.4 \u00b0C, 2 = 38.5\u201338.9 \u00b0C, 3 = 39.0\u201340 \u00b0C and 4 = >40 \u00b0C).",
            "startOffset": 25632,
            "title": "Safety assessments"
        },
        {
            "endOffset": 27056,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Materials and methods"
                }
            ],
            "secId": "s0035",
            "sentence": "Pre-specified halting/holding rules applied towards the decision on vaccine dose escalation included clinical systemic Treatment-Emergent AEs (vaccine-related Grade 3 Treatment-Emergent AEs beginning within 2 days following vaccination and persisting at Grade 3 for greater than 48 h), laboratory systemic Treatment-Emergent AEs (vaccine-related Grade 3 abnormalities beginning within 3 days following vaccination and persisting at Grade 3 for greater than 48 h), systemic Treatment-Emergent AEs (acute allergic reaction or anaphylactic shock following the administration of vaccine), positive urine pregnancy test, and a vaccine-related serious AE.",
            "startOffset": 26407,
            "title": "Safety assessments"
        },
        {
            "endOffset": 27540,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Materials and methods"
                }
            ],
            "refoffsets": {
                "b0140": {
                    "endOffset": 27539,
                    "startOffset": 27535
                }
            },
            "secId": "s0040",
            "sentence": "In this assay, 96-well plates were coated with 2 \u00b5g/mL of plant-produced Pfs25 antigen (Pfs25MF1E) [28].",
            "startOffset": 27436,
            "title": "Immunogenicity assessments"
        },
        {
            "endOffset": 22590,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Materials and methods"
                }
            ],
            "secId": "s0025",
            "sentence": "Subjects with a history of any severe allergic or anaphylactic type reaction to injected vaccines, a history of chronic or active immunodeficiency, autoimmune disease or use of immunosuppressive medications within 3 months prior to any planned vaccine dose, abnormal baseline clinical safety laboratory tests, or had received or planned to receive any other experimental drug/vaccine or licensed vaccine within 30 days prior to vaccination were also excluded.",
            "startOffset": 22131,
            "title": "Inclusion and exclusion criteria"
        },
        {
            "endOffset": 34069,
            "parents": [
                {
                    "id": "s0050",
                    "title": "Results"
                }
            ],
            "secId": "s0060",
            "sentence": "The subject who reported possibly related injection site pruritus also reported definitely related injection site pruritus that occurred outside the 28-day post vaccination period.",
            "startOffset": 33889,
            "title": "Safety and reactogenicity"
        },
        {
            "endOffset": 23378,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Materials and methods"
                }
            ],
            "secId": "s0030",
            "sentence": "Subjects received three doses of the vaccine on Study Days 0, 56 (\u00b14 days) and 168 (\u00b17 days).",
            "startOffset": 23285,
            "title": "Vaccination schedule"
        },
        {
            "endOffset": 36071,
            "parents": [
                {
                    "id": "s0050",
                    "title": "Results"
                }
            ],
            "secId": "s0060",
            "sentence": "The SAE in the 10 \u03bcg group occurred >28 days after the last vaccine dose and is therefore not included in Table 2.",
            "startOffset": 35957,
            "title": "Safety and reactogenicity"
        },
        {
            "endOffset": 36302,
            "parents": [
                {
                    "id": "s0050",
                    "title": "Results"
                }
            ],
            "secId": "s0060",
            "sentence": "Unsolicited and solicited Treatment-Emergent AEs are summarized by severity in Table 2.",
            "startOffset": 36215,
            "title": "Safety and reactogenicity"
        },
        {
            "endOffset": 30173,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Materials and methods"
                }
            ],
            "secId": "s0045",
            "sentence": "The number and percent of subjects experiencing at least one solicited AE were summarized by event term (e.g. pain, redness, swelling, fever, etc.).",
            "startOffset": 30025,
            "title": "Statistical analysis"
        },
        {
            "endOffset": 42313,
            "parents": [],
            "secId": "s0070",
            "sentence": "None of the AEs resulted in a death or discontinuation.",
            "startOffset": 42258,
            "title": "Discussion"
        },
        {
            "endOffset": 25631,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Materials and methods"
                }
            ],
            "secId": "s0035",
            "sentence": "Solicited local Treatment-Emergent AEs (injection site reactions) were pain, tenderness, erythema and induration/swelling; their severity was graded as mild, moderate or severe.",
            "startOffset": 25454,
            "title": "Safety assessments"
        },
        {
            "endOffset": 36215,
            "parents": [
                {
                    "id": "s0050",
                    "title": "Results"
                }
            ],
            "secId": "s0060",
            "sentence": "Both Serious AEs were considered to be unrelated to the study vaccine, and both subjects completed the study and were included in all analyses.",
            "startOffset": 36072,
            "title": "Safety and reactogenicity"
        },
        {
            "endOffset": 15102,
            "parents": [],
            "secId": "s0005",
            "sentence": "The spread of the disease in endemic regions can be reduced by the use of insecticide-treated bed nets and indoor residual spraying.",
            "startOffset": 14970,
            "title": "Introduction"
        },
        {
            "endOffset": 25108,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Materials and methods"
                }
            ],
            "secId": "s0035",
            "sentence": "Safety was assessed by recording baseline demographic information and medical history, monitoring vital signs, adverse events (AEs) and concomitant medications, and performing physical examinations and laboratory tests for hematology, chemistry and pregnancy.",
            "startOffset": 24849,
            "title": "Safety assessments"
        },
        {
            "endOffset": 33336,
            "parents": [
                {
                    "id": "s0050",
                    "title": "Results"
                }
            ],
            "secId": "s0060",
            "sentence": "Treatment-Emergent AEs occurring during the study period are summarized in Table 2.",
            "startOffset": 33253,
            "title": "Safety and reactogenicity"
        },
        {
            "endOffset": 15894,
            "parents": [],
            "refoffsets": {
                "b0015": {
                    "endOffset": 15807,
                    "startOffset": 15802
                },
                "b0020": {
                    "endOffset": 15807,
                    "startOffset": 15802
                },
                "b0025": {
                    "endOffset": 15807,
                    "startOffset": 15802
                },
                "b0030": {
                    "endOffset": 15807,
                    "startOffset": 15802
                },
                "b0035": {
                    "endOffset": 15807,
                    "startOffset": 15802
                },
                "b0040": {
                    "endOffset": 15807,
                    "startOffset": 15802
                },
                "b0045": {
                    "endOffset": 15893,
                    "startOffset": 15890
                }
            },
            "secId": "s0005",
            "sentence": "Most research activities on vaccine candidates including the licensed vaccine, Mosquirix, have been focused on pre-erythrocytic and asexual stages of the parasite life cycle [3\u20138], preventing the occurrence or multiplication of pathogenic asexual parasite forms [9].",
            "startOffset": 15628,
            "title": "Introduction"
        },
        {
            "endOffset": 24676,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Materials and methods"
                }
            ],
            "secId": "s0030",
            "sentence": "Since the TRA immunologic criterion for the Go decision (nine-month follow-up after the third vaccination, defined in Section 2.6) was not met (see Section 3.3), the follow-up period and duration of subject participation were six additional months for safety evaluation.",
            "startOffset": 24406,
            "title": "Vaccination schedule"
        },
        {
            "endOffset": 40196,
            "parents": [
                {
                    "id": "s0050",
                    "title": "Results"
                }
            ],
            "secId": "s0065",
            "sentence": "In the 30 \u00b5g dose group, statistically significant increases in anti-Pfs25 IgG titers, as compared to pre-vaccination levels, were observed 1 month after the 2nd (Day 84, p < 0.01) and 3rd (Day 196, p < 0.001) vaccinations (Friedman test followed by the Dunn\u2019s multiple comparison test, Fig. 1).",
            "startOffset": 39901,
            "title": "Immunogenicity"
        },
        {
            "endOffset": 30507,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Materials and methods"
                }
            ],
            "secId": "s0045",
            "sentence": "The solicited AEs were also summarized for each post-vaccination period and study day after each vaccination (Days 0\u20137) by event term and intensity grade for each vaccination period and overall, respectively.",
            "startOffset": 30299,
            "title": "Statistical analysis"
        },
        {
            "endOffset": 29917,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Materials and methods"
                }
            ],
            "secId": "s0045",
            "sentence": "The primary safety and reactogenicity outcomes included all subjects who received at least one dose of Pfs25 VLP-FhCMB and for whom safety data were available.",
            "startOffset": 29758,
            "title": "Statistical analysis"
        },
        {
            "endOffset": 31795,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Materials and methods"
                }
            ],
            "secId": "s0045",
            "sentence": "The Dunn\u2019s test was used to adjust p-values for multiple comparisons using GraphPad PRISM v.6.02 (GraphPad Software Inc.).",
            "startOffset": 31673,
            "title": "Statistical analysis"
        },
        {
            "endOffset": 32120,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Materials and methods"
                }
            ],
            "refoffsets": {
                "b0165": {
                    "endOffset": 32073,
                    "startOffset": 32066
                },
                "b0170": {
                    "endOffset": 32073,
                    "startOffset": 32066
                }
            },
            "secId": "s0045",
            "sentence": "The best estimate of %TRA, the 95% CI, and significance of inhibition from two or three feeds were calculated for each IgG as previously described [33,34] using a zero-inflated negative binomial model.",
            "startOffset": 31919,
            "title": "Statistical analysis"
        },
        {
            "endOffset": 42037,
            "parents": [],
            "refoffsets": {
                "b0160": {
                    "endOffset": 42036,
                    "startOffset": 42032
                }
            },
            "secId": "s0070",
            "sentence": "FhCMB engineered and transiently produced Pfs25 VLP-FhCMB in N. benthamiana and subsequently scaled it up for cGMP manufacturing in FhCMB\u2019s pilot facility [32].",
            "startOffset": 41877,
            "title": "Discussion"
        },
        {
            "endOffset": 23167,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Materials and methods"
                }
            ],
            "secId": "s0030",
            "sentence": "Since this was a dose-escalation study to assess the safety, reactogenicity and immunogenicity of Pfs25 VLP-FhCMB vaccine with a targeted human dose of 30\u2013100 \u00b5g, smaller numbers of subjects were assigned to the two lower dose groups.",
            "startOffset": 22933,
            "title": "Vaccination schedule"
        },
        {
            "endOffset": 41876,
            "parents": [],
            "secId": "s0070",
            "sentence": "This first-in-human, Phase 1 clinical study assessed safety and immunogenicity of the Pfs25 VLP-FhCMB, the plant-produced recombinant Pfs25 transmission blocking vaccine candidate against malaria developed by FhCMB for the prevention of disease caused by P. falciparum.",
            "startOffset": 41607,
            "title": "Discussion"
        },
        {
            "endOffset": 34432,
            "parents": [
                {
                    "id": "s0050",
                    "title": "Results"
                }
            ],
            "secId": "s0060",
            "sentence": "Across the three 28-day post-vaccination periods, the overall total proportion of subjects reporting at least one AE, as well as the percentage of subjects reporting vaccination-related AEs, tended to decrease (Supplementary material, Table S1).",
            "startOffset": 34187,
            "title": "Safety and reactogenicity"
        },
        {
            "endOffset": 31288,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Materials and methods"
                }
            ],
            "secId": "s0045",
            "sentence": "For hematology and clinical chemistry, descriptive statistics as well as change from baseline for each test was presented by vaccine treatment group and each visit.",
            "startOffset": 31124,
            "title": "Statistical analysis"
        },
        {
            "endOffset": 35956,
            "parents": [
                {
                    "id": "s0050",
                    "title": "Results"
                }
            ],
            "secId": "s0060",
            "sentence": "However, there were 2 Serious AEs: a breast abscess in the 10 \u03bcg group and a foot deformity in the 100 \u03bcg group (Table 2).",
            "startOffset": 35834,
            "title": "Safety and reactogenicity"
        }
    ],
    "docId": "S0264410X18311599",
    "metadata": {
        "asjc": [
            "1313",
            "2400",
            "2725",
            "2739",
            "3400"
        ],
        "authors": [
            {
                "email": null,
                "first": "Jessica A.",
                "initial": "J.A.",
                "last": "Chichester"
            },
            {
                "email": null,
                "first": "Brian J.",
                "initial": "B.J.",
                "last": "Green"
            },
            {
                "email": null,
                "first": "R. Mark",
                "initial": "R.M.",
                "last": "Jones"
            },
            {
                "email": null,
                "first": "Yoko",
                "initial": "Y.",
                "last": "Shoji"
            },
            {
                "email": null,
                "first": "Kazutoyo",
                "initial": "K.",
                "last": "Miura"
            },
            {
                "email": null,
                "first": "Carole A.",
                "initial": "C.A.",
                "last": "Long"
            },
            {
                "email": null,
                "first": "Cynthia K.",
                "initial": "C.K.",
                "last": "Lee"
            },
            {
                "email": null,
                "first": "Christian F.",
                "initial": "C.F.",
                "last": "Ockenhouse"
            },
            {
                "email": null,
                "first": "Merribeth J.",
                "initial": "M.J.",
                "last": "Morin"
            },
            {
                "email": null,
                "first": "Stephen J.",
                "initial": "S.J.",
                "last": "Streatfield"
            },
            {
                "email": "Vidadi.Yusibov@fhcmb.org",
                "first": "Vidadi",
                "initial": "V.",
                "last": "Yusibov"
            }
        ],
        "doi": "10.1016/j.vaccine.2018.08.033",
        "firstpage": "5865",
        "issn": "0264410X",
        "keywords": [
            "Malaria",
            "Pfs25",
            "Plant-produced",
            "Transmission blocking vaccine",
            "Virus-like particle"
        ],
        "lastpage": "5871",
        "openaccess": "Full",
        "pub_year": 2018,
        "subjareas": [
            "BIOC",
            "IMMU",
            "MEDI",
            "VETE"
        ],
        "title": "Safety and immunogenicity of a plant-produced Pfs25 virus-like particle as a transmission blocking vaccine against malaria: A Phase 1 dose-escalation study in healthy adults"
    }
}